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The synthesis of the benzoid-based lipoxine A4 (LXA4) is the focus of this study specifically, the 
para substituted benzoid system. LXA4 is an endogenous agonist binding with high affinity to 
(ALXR) receptor that initiate it to display anti-inflammatory and antioxidant activities. 
Arachidonic acid is the cascade of LXA4 and its derivatives. These compounds belong to the 
biological active eicosanoids, which are characterized by its consistent of 20 C-atoms.   
Based on structure activity relationship (SAR) of LXA4, several studies postulated wide range of 
modification and functionalization. Benzoid based LXA4 analogues have studied by several 
research groups where the focus was on the O- and M-substituted benzoids. Herein, a total 
synthesis approach towards some structural mimics of LXA4 was conducted. Where, the target 
was the benzoid based LXA4. Specifically, the p-substituted benzoid suggesting that these 
analogues could cover the same conformational space as the native LXA4.  
 





The project approach is based on using commercially available starting materials such as 2-
deoxy-D-ribose, toluene and p-cresol to assemble the desired molecules. 
Important reactions in the course of the synthesis includes: 
C1-C8 building block: Wittig reaction, Parikh-Doering oxidation, hydrogenation of the alkene, 
protecting group operations. 
C15-C21 building block: Friedel-Craft acylation, O-alkylation, reduction by sodium borohydride. 
Key reaction of the synthesis is the Wittig reaction between the two coupling partners. This 
reaction leads to the selective formation of the trans-olefin. The formation of the lactone ring 
intermediates 17 and 16 during the de-protection of 1, 2-diol moiety has been studied in details 
with the help of computational chemistry (Figure 1). The last part of the thesis reveals an initial 
trial of another suggested approach based on “Ullmann type” reaction. The total synthetic 
strategy was successfully applied within 14 steps out of 17 were successfully performed 
obtaining intermediates 16 and 17 in a good yield. The compliment of the steps includes short 
reactions of lactone ring hydrolysis in basic medium in addition to reduction of the ketone 
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SN Nucleophilic substitution 
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LXA4 is an endogenous agonist binding with high affinity to (ALXR) receptor. It is known as 
formyl peptide receptor 2 (FPR2), which displays anti-inflammatory and antioxidant activities 
[1-3]. LXA4 also shows partial agonist activity on binding with cysteinyl leukotriene receptors 1 
and 2 [3, 4]. LXA4 can suppress cytokine signaling2 when binding to nuclear receptor aryl 
hydrocarbon [5]. Furthermore, LipoxinA4 interacts with CB1 receptor and exhibits positive 
allosteric modulation [6, 7]. LXA4 involved in modulation of several inflammatory disorders 
such arthritis, asthma and ischemia [8-10, 132]. According to Pamplona et al. LXA4 is positive 
allosteric modulator (PAM) of CB1 cannabinoid receptor weather it is administered 
exogenously or it is produced endogenously [6, 7].  
As a natural product LXA4 can only be isolated in minimal quantities as many other natural 
products. It is produced in the body on demand and rapidly metabolized, which means that its 
accumulation at the site of the inflammation is short lived. These obstacles were realized upon 
the investigation and the study of these compounds. Thus, it reduces the possibility of applying 
further studies and investigations on these important pharmacological agents. Subsequently, a 
novel range of LXA4 analogues were designed and synthesized to get the structure activity 
relationship (SAR). In addition to, the evaluation of these novel analogues for pharmacological 
activity and resistance to the degradation for enhanced biological properties. Several research 
groups have conducted extensive studies indicating some functionalities and stereocenters 
that are essential to retain the biological activity according to SAR [9, 11-14]. 
This thesis describes our contribution in the continuous efforts towards mimicking the 
structure of the native LXA4. Our approach targeted a class of LXA4 analogues that are based 
on replacing the triene unit with a stable aromatic moiety in a substituted benzoid system. 
Benzoid based LXA4 analogues have been under the spot of study for many research groups 
where the focus was on the O-and M-substituted benzoids (Fig 2).  
Herein, we present in our research a total synthesis approach where the focus is on the p-
substituted benzoid suggesting that these analogues could cover the same conformational 




















1.1 THE GOALS AND DESIGN OF THE PROJECT 
Herein is proposed the construction of LXA4 analouges based on benzoid system (Fig 2, 3). The 
benzoid scaffold allows for a more effective and modular construction of the basic framework 
and the formation of a variety of analogues in a relatively straightforward manner. It is assumed 
that the various analouges cover the same conformational space as LXA4.  However, each 
analogue is restricted to a particular configuration of the triene-portion of LXA4.  This could 
impose entropically very favorable binding characteristics, which means that the analogue 
would not need to lose too many degrees of freedom in the binding process compared to the 
LXA4 itself. The construction of the proposed analogues will be first attempted. Our project 
goal is to introduce an appropriate organic synthesis strategy to produce the proposed 
analogues see (Fig 3) from easy and commercially available starting materials. The aims of the 
thesis are: 
 
1. Plan and design a synthetic route to benzene analogues of lipoxin A4 
 
2. Develop the synthetic route towards lipoxin A4 analogues 
 
3. Prepare some structurally similar analogues. 
 
4. Investigate alternative synthetic routes to generate simpler analogues 
 












1.2 RETROSYNTHESIS  
The targeted molecules 17 and 18 consist of two main partners that show from the central 
disconnection A. The first disconnection A removes the aldehyde moiety 5 revealing the Wittig 
salts 9 and 13. In the forward direction, this is envisioned using Wittig coupling reaction. 
Further disconnection of both Wittig salts 9 and 13 removes the phosphate group retaining the 
benzylic brominated compounds 8 and 12. While in forward synthesis, they could be performed 
by SN2 reaction with the triphenylphosphine  
Disconnection of the benzylic brominated para benzoids 8 and 12 reveals the para alkyl 
benzoids 7 and 11. While the forward synthesis in case of compound 7 is based on the use of 
NBS within a thermal reaction where the heat is the radical initiator. On the other hand, the 
forward synthesis of compound 11 is based on the use of NBS with benzoyl peroxide as the 
radical initiation in a benzylic bromonation induced by visible light reaction  
Latest disconnection D of the benzylic ether 11 gives the alkyl bromide and the para cresol, 
which is forward synthesized by O-alkylation in an SN2 reaction mechanism. While in case of 
the acylated toluene 7 the disconnection gives the toluene and its acyl chloride partner. The 
forward synthesis can be performed using Friedel-Craft acylation on the toluene to give the 
para acylated toluene. 
 On the other pathway, further disconnection of the aldehyde 5 gives the alcohol 3. While, the 
forward synthesis of this aldehyde can be performed by the oxidation of the corresponding 
saturated alcohol of the alcohol 3 using Parikh-Doering oxidation. 
 Disconnection F removes the ethyl acetate moiety revealing the original protected sugar 2 and 
the phosphate salt. Compound 3 can be forward synthesized by Wittig reaction between the 
Wittig salt and the protected sugar 2. 
As 1, 2-diol containing sugar 1 it could be protected in a form of acetonide 2 when it couples 























1.3 BIOLOGICAL BACKGROUND 
1.3.1 Cannabis and cannabinoids 
The plant Cannabis sativa L., family (Cannabaceae), is an Indian hemp represents one of the 
oldest cultivated plants. Its origin is the plains of Central Asia and from there has been 
distributed widely around the world [15, 16]. Cannabis was cultivated for its herbal contents, 
natural fiber and oil. Cannabis derivatives have been used as therapeutic agents across the 
ancient world for more than 4000 years. Several therapeutic uses have been reported such as 
digestive, appetite stimulant, analgesic, anticonvulsant, tranquilizer, anesthetic, anti-
inflammatory, antibiotic, antiparasite, antispasmodic, and others [17]. The two most 
referenced cannabinoids preparations, are marijuana (dried leaves and female flower heads) 
and hashish (cannabis resin) [18]. In 19th century Europeans used cannabis extracts in the 
treatment of epilepsy, rheumatism, menstrual cramps, convulsions, chorea, hysteria, 
depression, tetanus, gout, and neuralgia [19]. 
Cannabis extracts contains more than 460 compounds around 70 out of them are considered 
as phytocannabinoids [20]. The prototype psychoactive phyto cannabinoid of cannabis is 
Δ
9
tetrahydrocannabinol, commonly known as Δ
9
-THC,  The identification of the  Δ
9 
–THC was 
the first step to develop novel  synthetic  cannabinoids, The chemical synthesis of the 
cannabinoids was followed by accumulating research into basic structure activity relationships 
{SAR} and their metabolic routs [21, 22]. The need for more potent and less lipophilic analogues 
that avoid the unwanted psychoactive effects led to the first synthetic drug mimics the action 
of Δ
9
THC “nantradol” synthesized by Pfizer Inc. in 1980. Soon after, replaced by levonantradol 
(Nantrodolum
®
) [23].  The term “Cannabinoid” refers to a set of oxygen-containing C21 
aromatic hydrocarbon compounds that occur naturally in the plant Cannabis sativa. Now, the 
term is expanded to involve all naturally occurring or synthetic compounds that can mimic the 
actions of plant-derived cannabinoids or that have structures similar to those of plant Cannabis 
sativa [24-26].  
A separate term” phytocannabinoid” (pCB)   refers to lipophilic molecules naturally occurring 







1.3.2 The endocannabinoid system 
The endogenous cannabinoid system is comprised of cannabinoid receptors (CBrs), their 
endogenous ligands, i.e. endocannabinoids, and enzymes for their biosynthesis and 
degradation [28]. Endocannabinoids comprise a family of eicosanoid CBrs [29, 30] present in 
the brain and in peripheral tissues. Wilson and Nicoll [31] described that endogenous 
cannabinoids mediate retrograde signaling that may be involved in the inhibition of 
neurotransmitter release.  Endocannabinoids differ from neurotransmitters as they are 
synthesized rapidly on demand, not in advance, from membrane phospholipids precursors 
upon stimulation and they are not stored in vesicles rather their precursors [32]. 
N-arachidonoyl ethanolamine (anandamide, AEA) and 2-arachidonoyl glycerol (2-AG) are the 
major endocannabinoid ligands act basically at cannabinoid receptors CB1 and CB2. Other 
endocannabinoids have also identified such as noladin ether, virodhamine, and N-arachidonoyl 
dopamine (NADA) but their biological activity and metabolism has not yet been fully identified 
[20]. Most of endocannabinoids have greater affinity for CB1 Than CB2 except 2-AG that has 
relatively equal affinity for both CB1 and CB2,while  virodhamine, unlike the others, acts as CB1 
antagonist /invers agonist and  has greater affinity for CB2 receptors [33, 34]. 
Endocannabinoids mediate several signals that regulate numerous aspects of mammalian 
neurophysiology, including suppress pain sensitivity, feeding, emotional state, learning and 
memory, and reward behaviors [35-37].Anandamide and 2-AG are widely distributed 
throughout the body. They are the main ligands among other endocannabinoids, though 2-AG 
expressed at much higher concentrations than anandamide. These endocannabinoids have 
been found in the brain, retina, and several peripheral tissues that involve the heart, spleen, 
liver, kidney, thymus, reproductive system and skin [38].The biosynthesis of endocannabinoids 
has not yet fully understood.  It is known that anandamide is synthesized by calcium dependent 
transacylase enzyme (CDTA) that led to migration of arachidonic acid (AA) from the sn-1 
position of membrane phospholipids to the primary amine of phosphatidylethanolamine (PE) 
to form N-arachidonoylphosphatidyl-ethanolamine (NArPE).Hydrolysis of (NArPE ) to produce 





 2-AG is synthesized from arachidonoyl acid and preceded by formation of diacylglycerol (DAG) 
species by sn-1-specific diacylglycerol lipase- α and -β (DAGL α and DAGL β [41]).  
DAGL α is required for 2-AG formation in the brain while DAGL β in peripheral tissues such as 
the liver and spleen [42, 43]. DAG precursors are synthesized from membrane phospholipids 
to form sn-2 arachidonoyl phosphatidylinositol 4, 5-bisphosphate (PIP2) then hydrolyzed by 
phospholipase C (PLC β) to form 2-AG [44]. 
Anandamide transfers to its target cells by passive diffusion where exert its biological effects 
and rabidly degraded. Anandamide degradation seems to be happened by the serine hydrolase 
enzyme fatty acid amide hydrolase (FAAH) to form arachidonic acid and ethanolamine [33]. 
Soon after 2-AG migrates into cells by simple and passive diffusion, it is degraded by enzymatic 
hydrolysis of the ester bond. Presynaptic monoacylglycerol lipase (MAGL) is the major enzyme 
that hydrolyze 2-AG, serine hydrolases (SH) and FAAH enzymes may regulate 2-AG hydrolysis 
[45, 46]. 
1.3.3 Cannabinoid receptors type 1 
The existence of unknown (GPCRs) receptors bind to cannabinoids and couple to inhibition of 
adynylil cyclase to decrease the (cAMP) accumulation was first demonstrated by Howlett [47, 
48]. In 1988 the same group characterized CB1,  receptor needed for canabinoids  to mediate 
their action [49].The cannabinoid receptor, CB1, was first  cloned from rat in 1990   [50] 
followed by the second cannabinoid receptor CB2 ,which was cloned in 1993 [51] 
The two different cannabinoid receptors  CB1 and CB2 belong to G Protein Coupled Receptors 
(GPCRs), The largest family of cell surface receptors responsible for transducing signals from 
the outside to the inside of the cell. GPCRs are divided into 6 classes (A-F) based mainly on 
sequence homology and functional similarity. The largest and most studied class is the 
rhodopsin-like class A. This class, which includes rhodopsins, adrenergic, and cannabinoid 
receptors [52], is characterized by a heptahelical arrangement of membrane spanning α –
helical transmembrane domains (TMDs). They are connected by intervening three extracellular 
loops (EC1-EC3) preceded by Extracellular amino terminal (N terminus) and three intracellular 
loops (IC1-IC3). TM7 followed directly by intracellular cytoplasmic H8 and a carboxyl terminus 





The 7TM bundle also known by highly conserved motifs that are characteristic of GPCRs. These 
include the S(N)LAxAD in TM2,the E/DRY motif in TM3, theWX(9)P in TM4,the CWXP in TM6 
and the NPXXY motif in TM7 [53,54]. It was found that human CB1 receptors are composed of 
472 amino acids and those in rats are 473 amino acids long  [50] (Fig. 4). The CB2 receptor was 
determined to be 360 amino acids long and shares 44% of its overall sequence with the CB1 
receptor, with 68% similarity through the transmembrane domains [51]. 
 
Figure 4. Schematic representation of rat CB1 with three extracellular loops E1 – E3 and three intracellular loops C1 - C3, 
extracellular N-terminus, transmembrane α helix TM1 – TM7 and intracellular C-terminus ended with helical segment H8 and 
palmitoylation site on Cys residue denoted to by two sided arrows. Shaded circles marked the highly conserved residues while 
the arrows denote the most highly conserved residues of each helix. A conserved disulfide bridge Cys – Cys residues on E2 loop 
marked also by two sided arrows. (From Shim et al., [54]). 
1.3.4 GPCR receptors life cycle 
 It seems that GPCRs are synthesized, folded, and assembled through the endoplasmic 
reticulum (ER). Then migrate to Golgi complex where they subject to final modifications. After 
this modifications (e.g. palmitoylation methylation and glycosylation) GPCR receptors transfer 
to embedding themselves through the plasma membrane in inactive state. GBCR undergoing 





commence downstream signaling pathways [55].The level and duration of CB1 signaling activity 
is controlled by desensitization process. It first begins with phosphorylation of activated 
receptors by GPCR protein kinases (GRKs) blocking the receptor from binding to G proteins. 
Phosphorylation of CB1 sets the stage for the second step, which is binding to protein β-
arrestin1 and β-arrestin2 immediately [56].  
The agonized CB1-arrestin complex associates with clathrin–coated pits to initiate GPCR 
internalization. Β-arrestins also acts as scaffolds in CB1- endosome - based signaling pathways. 
The arrestin bound CB1 may be dephosphorylated leaving CB1 free to migrate to plasma 
membrane. Internalized CB1 may also traffic from endosomes to lysosomes where they are 










Figure 5. Model of the GPCRs life cycle. GPCRs are synthesized at the endoplasmic reticulum (ER) and sent to the Golgi complex 
where they are modified then transfer to the plasma membrane. Upon agonist stimulation, GPCRs bind and activate a G protein 
commencing downstream signaling pathways. Duration of CB1 signaling activity controlled by desensitization a process begins 
with phosphorylation and removal of the receptors from the cell surface (internalization) by GRK and β-arrestins proteins. 
Internalized receptors may targeted to lysosomes for degradation, or resensitized by recycling back to the cell surface. (Stadel 
et al., [55]). 
1.3.5 Receptor activation states 
A two-state model of GPCR activation suggested by Leff [58], a receptor can be exist in two 
states, the fully active state R* and the inactive state R. Both states, R* and R, are in dynamic 





pharmacophoric features of the ligand binding to the receptor. Agonists can alter the 
equilibrium to the active state R*, while the antagonists alter the equilibrium to the inactive 
state R [59]. Most GPCRs possess some degrees of constitutive activity R' (a basal level of 
activation in the absence of any endogenous or exogenous agonist) so, we can look at the 
Inverse agonists as ligands that decrease the level of receptor activation below basal levels and 
suppress signal transduction [60]. Neutral antagonists bind to the receptor keeping the basal 
levels without stimulating or inhibiting the receptor, they occupy the binding sites and 
canprevent other ligands from binding to the receptor. Full agonists induce the maximal 
possible level of activation, while partial and weak partial agonists activate the receptor above 
basal levels but not maximally, they cannot elicit full activity even at saturating concentrations 
[61]. This observation led to adaptation of the model of GPCR two state activation to suite    
multiple activation states [62] with distinguishing biochemical characteristics, including extent 









Figure 6. GPCR activation states. Full agonists promote the maximum active R* state of the receptor and enhance the biological 
activity and signal transduction of the receptor while inverse agonists decrease the level of receptor activation below R' levels 
and suppress signal transduction. Antagonists bind the orthosteric site competitively but do not alter the equilibrium of R and 






1.3.6 CB1 receptors tissues distribution  
CB1 receptors are found in rat and human brain tissues predominantly in the central and 
peripheral nervous system[50], where they mediate  presynaptic inhibition of transmitter 
release that include acetylcholine, noradrenaline, dopamine, 5-hydroxytryptamine, g-
aminobutyric acid, glutamate, D-aspartateand cholecystokinin [52,63]. 
 CB1 has been expressed with a high level in cerebral cortex, hippocampus, basal ganglia, and 
cerebellum, less abundant in hypothalamus and spinal cord, and very low level in the brainstem 
[52, 64]. However, it has also been identified in a number of peripheral organs and tissues with 
a lower level than in the central and peripheral nervous system .It is found in heart, kidney, 
colon, pancreas, spleen, placenta and liver [65]. It can also expressed in gastrointestinal tract, 
adipose tissue, thyroid, adrenals, skeletal muscle, hepatocytes, and reproductive organs 
andendocrine cells of the pancreas [66, 67]. 
The CB1 receptor along with its agonist and antagonist cannabinoids are a valuable therapeutic 
target for a number of disorders.  including neurodegenerative diseases , cancer, neuropathic 
and inflammatory pain, obesity [68] treatment of anorexia in patients who suffer from AIDS 
wasting syndrome, reducing nausea and vomiting associated with chemotherapy treatment 
[69], and relief of neuropathic pain in multiple sclerosis [70].  Their activation can affect 
processes such as cognition and memory, alter the control of motor coordination, and induce 
signs of analgesia, autonomic function and sensation [71].  
Cannabinoid drugs produce a “tetrad” of characteristic pharmacological effects: 
antinociception, hypothermia, a decrease in general mobility (sedation), and catalepsy, these 
combinations of pharmacological side effects have been accepted as a screening procedure 
[72]. The CB1-selective antagonist SR141716 was able to block the unwanted effects of most 








                     Figure 7. Tissue distribution of the human CB1 and CB2 receptors in the body [75]. 
1.3.7 CB1 Signal transduction 
CB1 receptor when activated, couples to the   inhibitory Gi/o proteins. The activation of these 
inhibitory G-proteins by CB1 linked to the inhibition of adenylatecyclase .The enzyme 
responsible for synthesizing cAMP production from ATP. That leads to decrease of cAMP 
accumulation.  The cAMP acts as a cellular secondary messenger andmediates processes 
including the metabolism of glycogen, sugar and lipids [47, 48]. However, in certain 
circumstances, CB1R can couple to Gs proteins. , It has been reported that in pertussis-
pretreated cells, CB1R stimulation leads to adenylyl cyclase activation [76, 77]. The ability of 
cannabinoids to modulate cellular levels of cAMP has been demonstrated to regulate many 
aspects of cellular function, such as the contractile activity of smooth muscle, the gating 
properties of ion channels on neuronal cell [78]. CB1receptor couples predominantly through 
Gi/oproteins to certain subtypes of voltage-gatedcalcium (Ca2+) channels associated with the 
inhibition of N, P/Q and L-types voltage-dependent (Ca2+)  channels [79] and activation of A-
subtype and inward-rectifying K+ channels [80,81].  Cannabinoids suppress neuronal 






CB1 activation may also stimulate mitogen-activated protein kinase (MAPK). The (MAPK) 
pathways can regulate cell proliferation, cell differentiation, cell movement and cell death [83]. 
MAPK cascades include pathways leading to activate ERK1/2 [84], c-Jun N-terminal kinase (JNK), 
p38 MAPK [85, 86], and (PI3K) phosphatidylinositol 3-kinase [87]. 
CB1 receptor-mediate production and release of NO from endothelial and neuronal cells.CB1 
stimulation of NO-sensitive guanylylcyclase leads to increasing of cyclic GMP production [88, 
89]. NO is synthesized in most biological tissues and it involves in several biological functions 
including neurotransmission, vasodilatation and macrophage function [90]. 
 
Figure 8. Model of CB1 signal transduction. On stimuli CB1 associates to heterotrimeric G-protein results in a release of (α-β Ύ ) 
subunits of  G- protein, which have a negative impact on cellular production of cAMP, activates K+A and K+IR channels, and 
inhibits Ca2+ channels. It can also recruit β-arrestin to the plasma membrane. When stimulated, CB1 can activate MAPK, 
phosphatidylinositol 3-kinase, and FAK, among other pathways. (Modified from [65]). 
1.3.8 CB1 receptor agonists 
CB1 receptor agonists can be divided into five different groups: Classical cannabinoids, Non-
classical cannabinoids, aminoalkylindole cannabinoid, and eicosanoid cannabinoids that 






Classical cannabinoids are ABC - tricyclic terpenoid derivatives bearing a benzopyran moiety. 
They are insoluble in water but soluble in lipids, alcohols, and other nonpolar organic solvents.  
(Δ 9- THC)  Δ 9-tetrahydrocannabinol the prototype of the classical  cannabinoid agonists is the 
main constituents of the plant cannabis sativa, this phytocannabinoid agonist which was known 
by its psychoactive effects long before discovery of CB1/CB2 receptors.  Δ 9 –THC  exhibit low 
affinity for both receptors and acts as partial agonist. Other pharmacologically active 
constituents of the plant cannabis sativa is (-)-Δ 8 -THC (cannabinol. [92]).  
HU-210 is a synthetic analogue produced by replacing the pentyl side chain of Δ8 –THC with a 
dimethylheptyl side chain. It is developed by Mechoulam to work as a radioligand labeled probe 
binding to cannabinoid receptors [93]. It has a high affinity for both CB1 and CB2 receptors. It 
also displays high potency and acts as a cannabinoid receptor agonist and exhibits a long term 
of action in vivo [24].  
Non classical agonists consist of bicyclic and tricyclic analogues that are biological mimetic of 
Δ9-THC, identified by lack of the pyran ring of Δ9-THC. They are represented by CP55, 940 
developed by Pfizer [94]. The [3H]CP55, 940 exhibits high affinity and efficacy for both CB1 and 
CB2 recptors and acts as a standard research tool for probing the cannabinoid receptors, used 
as a key radioligand to identify CB1 receptor [49]. CP55244 and HU-308 are examples for this 
class. They are closely related to the classical cannabinoids. 
Aminoalkylindoles structure, from the pharmacophoric point of view may have a three-point 
attachments  i) the morpholinoethyl group ii) the carbonyl group  iii) the naphthalene ring at 
the C7 position[95]. The morpholinoethyl group or another cyclic structure was required for 
binding and exert activity of aminoalkylindoles [96]. Aminoalkylindoles represented by WIN55, 
212-2, it is important research tool for investigation of the endocannabinoid system. Its 
potential as non-steroidal anti-inflammatory agent showing a 7-fold difference in potency for 
hypomobility versus potency for antinociception and hypothermia [97] with a higher affinity for 
(CB2) receptors than for CB1 receptors in the brain (Ki = 1.89 nM (CB1) and 0.28 nM (CB2), 
[98]).   
Eicosanoids, since the discovery of endogenous cannabinoids especially anandamide and 2AG, 





considered a template for the modification of CB1 agonists for eicosanoid compounds [99,100]. 
The modification of a polar ethanolamido head group of anandamide produce several CB1 
agonists. The (R)-Methanandamide is similar to anandamide except for a methyl group added 
to the 1’ carbon [101].  
The importance of this compound came from its ability to resist the anandamide hydrolysis by 
amidohydrolase. Its enzymatic resistance and relatively high potency, 4 folds higher than 
anandamide, make it effective biological tool with selectivity for the CB1 receptor [102]. The 
modification of anandamide head group by substitution of chloro or fluoro group instead of 2-
hydroxyl group resulted ACEA (AM881) and (O-585) ligands respectively. Both ligands are CB1 
selective and exhibit high affinity and efficacy [88, 99].   
Hybrid cannabinoids resulted from the combination of classical and non-classical cannabinoids 
structural features. The modification of The Southern aliphatic hydroxyl (SAH) pharmacophore 
have been developed to produce novel analogs [103-105]. The β-hydroxypropyl analogue is a 
good representative for this class. It has a higher affinity than the α-axial epimer.   
1.3.9 Cannabinoid antagonists – inverseagonists 
Most Endocannabinoid antagonists or inverseagonists are diarylpyrazole compounds. The 
selective CB1 receptor antagonist SR141716A (Rimonabant) was developed by Sanofi [74,107]. 
It is used in medicinal treatment for a number of disorders such as Alzheimer’s disease, 
schizophrenia/and obesity [106]. It binds selectively to CB1 receptor with a very high potency. 
SR141716A has the ability to block or reverse the effects induced by cannabinoid agonists at 
CB1 receptors, both in vitro and in vivo [52,108]. Structural analogues of SR141716A have been 
developed, AM251andAM281 are both selective to CB1 receptor with lower affinity than 
SR141716A [109].  They are able to displacing [3H] SR141716A and [3H] CP-55,940 in CB1 
receptor membrane preparations and they can block or reverse the effects induced by 
cannabinoid agonists at CB1 receptors [110,111]. 
 Another CB1 receptor selective antagonist LY320135 developed by Eli Lilly, it is less potent than 













1.3.10  Allosteric modulation 
In 1963, “Monod, Changeux and François Jacob on ‘allosteric proteins and cellular control 
systems’”  noticed, In the field of enzymology, that the chemical structure of inhibitors was 
often very different from the substrate of the enzyme suggesting  another binding site referred 
to as ”allosteric site” accommodated these inhibitors through which they transmitted their 
effect to the substrate site [113]. According to this concept, the activity of a receptor can be 
modulated by ligands that bind to allosteric sites – sites which are located away from the 
orthosteric sites and does not exhibit any overlap with the orthosteric site. The binding of a 
ligand to allosteric site can alter the receptor conformation, thereby either enhancing (positive 
allosteric modulator, PAM) or slowing (negative allosteric modulator, NAM) the interactions 
carried out at the orthosteric site [114,115]. Allosteric ligands have several advantages over 
orthosteric ligands. Probe dependant which mean that allosteric modulators exert their effects 
only in the presence of orthosteric ligands and thereby we can look at them as fine tuners. 
Additional advantage of allosteric modulator is their saturable effects which known as “ceiling- 
effect” and no more amount of allosteric ligand can affect orthosteric / allosteric ligands 
cooperativity [116].  
This advantage enabled the allosteric modulators to avoid the harmful and unwanted 
physiological side effects of the orthosteric agonists [117]. Toxicity, desensitization, long-term 
changes in receptor up/down regulation and psychoactivety can be adjusted by allosteric 
modulators that have the potential to overcome these negative effects [114]. 
Functional assays along with kinetic association and dissociation assays of the (radio) ligand-
receptor interaction are often used to determine an allosteric ligand potentiality [115]. The 
binding of an allosteric ligand induces a conformational changes in the receptor, thereby 
altering the rates at which the orthosteric ligand associates or dissociates from its binding site 
[118].The need to describe different  interactions of receptor – ligand have been met by Several 
mathematical models. One of the first and most simple models is the allosteric two-state model 






1.3.11  Allosteric Modulators of the CB1 Receptors 
Allosteric ligands that modulate CB1 Receptor have been developed soon after identifying CB1 
allosteric sites.  Org 27569 the prototype of allosteric ligands exhibits interesting effects on 
CB1, it increases the affinity and decreases the efficacy of CB1 agonists, [117,119], by blocking 
the agonist-induced conformational change at TM6. Org 27569 traps the receptor in a distinct 
agonist-bound, but inhibiting conformational changes required for receptor signaling [120].1-
(4-Chlorophenyl)-3-[3-(6-pyrrolidin-1-ylpyridin-2-yl) phenyl] urea (PSNCBAM-1) [121] is 
another allosteric modulator type for CB1. These compounds modulate electrically evoked 
contractions in the mouse vas deferens [117], affects CB1 ligand modulation of synaptic 
transmission [122] and have hypophagic effects in vivo [121]. They display a contradictory 
pharmacological profile increasing the specific binding of the CB1 receptor agonist [3H] 
CP55940 but producing a concentration-related decrease in CB1 receptor agonist efficacy. The   
3b-(4-methylphenyl)-2b-[3-(4-chlorophenyl)isoxazol-5-yl]tropane (RTI-371) is  the positive CB1 
allosteric modulator has been discovered by the way, when Navarro and his colleagues  were 
searching for treatment of cocaine addiction investigating indirect dopamine agonists ,they 
noticed that  RTI-371 blocks cocaine-induced locomotor stimulation. They subject this 
compound for screening through functional assays for activity at other CNS receptors. They 
demonstrated that RTI-371 is a positive allosteric modulator of the human CB1 receptor. Other 
DAT-selective inhibitors on CP55940-stimulated calcium mobilization was characterized in a 
calcium mobilization-based functional assay for the hCB1 receptor [123]. Recently, a new 








Figure 10. Chemical structure of representatives for CB1 allosteric modulators. 
1.3.12  Lipoxin A4 is an endogenous allosteric ligand for CB1  
Lipoxins are trihydroxy-eicosatetraenoic acids, derived from arachidonic acid with the four 
double bonds in conjugation, which were the first lipid mediators to be discovered that were 
involved in the resolution phase of inflammation. There are at least three routes to the 
biosynthesis of lipoxins through cell-cell interactions when distinct types of cells are in close 
proximity during inflammatory responses. The two enzymes lipoxy-genase (LO) and 
cylcooxygenase (COX)-2 have a crucial role in lipoxins biosynthesis [124,125]. One of the 
recognized mechanisms of lipoxins biosynthesis is catalyzing  arachidonic acid into 15S-
hydroxyeicosatetraenoic acid (15S-HETE) by  lipoxygenase  (15-LO) via Monocytes, eosinophils, 
and airway-epithelial cells .15S-HETE is rapidly taken up by neutrophils and converted to lipoxin 
A4 by a 5-LO- catalyzed reaction [124]. 
The second pathway go through the vasculature that activate 5-LO, present in myeloid cells, 
[126] to produce leukotriene A4 (LTA4) and then converted to lipoxins by 12-LO, which is 
present in platelets. This process is determined by cell-cell interaction [127].The third 
important route is known by the aspirin triggered 15-epi-LX (ATLs) pathway. The reaction is 
initiated by aspirin to acetylate the cyclooxygenase COX-2, in the stimulated endothelial and 
epithelial cells, altering the catalytic activity of the enzyme to produce 15RHETE in lieu of 
prostanoid biosynthesis. The 15R-HETE is released from endothelial and epithelial cells and 





[128]. The 15-epimer lipoxins possess most of the parent lipoxins biological features added to 
its higher potency and efficacy [129].  Lipoxins can serve for pro – resolution of inflammation 
and acts as endogenous mediator that is anti-inflammatory agent. Lipoxins exhibit vasodilatory 
and counter regulatory roles in vivo and in vitro models. Lipoxins promote vasorelaxation and 
relax the aorta and pulmonary arteries [130,131]. 
Lipoxin A4 is an endogenous agonist binding with high affinity to (ALXR) receptors, also known 
as formyl peptide receptor2 (FPR2), where display anti-inflammatory and antioxidant activities 
[1-3]. LXA4 also shows partial agonist activity on binding with cysteinyl leukotriene receptors 1 
and 2 [3, 4]. LXA4 can suppress cytokine signaling2 when binding to nuclear receptor aryl 
hydrocarbon [5]. Furthermore, LipoxinA4 interacts with CB1 receptor and exhibits positive 
allosteric modulation [6, 7]. LXA4 involved in modulation of several inflammatory disorders 

















1.4 CHEMICAL BACKGROUND TOWARD THE SYNTHESIS OF LXA4 ANALOGUES 
Based on the retro synthesis study (Scheme 1) we were able to design the forward synthesis. 
This part of the introduction includes an overview on the methodology applied in order to 
obtain the desired analogues. Furthermore, it discuss the theory behind the reactions by 
discussing the proposed mechanism of each reaction.  
 






1.4.1 Preparing the aldehyde from the sugar  
This part of the synthesis was based on the strategy postulated earlier by Philips ED et al. as 
shown (scheme 3). Minor modifications were applied on the same strategy in order to obtain 
the intermediate 3. Different strategy was applied in this thesis starting from intermediate 3 
until the key intermediate 5 (section 1.4.1.4). 
 
Scheme 3. Earlier synthetic research on the key intermediate 
1.4.1.1 1, 2-diol prorection of the 2-deoxy-D-ribose. 
 
Scheme 4.Protection of 2-deoxy-D-ribose 
There are many protecting groups that show great efficiency in protecting alcohols as 
trialkylsilyl (R3Si), tetrahdropyranyl (THP), benzyl ether (OBn) and they are used in different 
conditions. In this case we are dealing with the protection of a 1, 2-diol system (two adjacent 
hydroxyl groups). This kind of protection could be performed by making an acetals from these 
two adjacent hydroxyl groups. The acetal formation reactions are a reversible process and 






Scheme 5. General mechanism of acetal formation 
In this reaction 2-methoxypropene was the protecting agent for the 1, 2-diol system in a 
reaction of acetonide formation. 2-methoxypropene is an electron rich used in the 
monoprotection of  several groups, such as alcohols of different types like aliphatic and allylic 
alcohols, peroxides, cyanohydrins, alpha hydroxyl ketones , 1,2 diols and 1,3 diols. In addition, 
it is used in other applications such as formation of 2-methoxyallyl halides and substituted 
furans its participation in pericyclic reactions [133]. Acetonide formation proceed when the 
lone pair of the hydroxyl group act as a nucleophile and attack the electrophile, which 
expressed in the protecting group. This leads to the formation of a new O-C bond between both 
of them, in a process of proton transfer leads to some resonance movement. As a result a new 
electron rich position which is the formed carbonyl group with a positive charge on the oxygen  
after the removal of methanol fraction from the compound. The lone pair on the other alcohol 
partner will have the tendency to attack on this carbonyl group completing the protection 














Scheme 6. Mechanism of acetonide formation 
1.4.1.2 Wittig reaction of the protected sugar. 
 
Scheme 7. Synthesis of the unsaturated alcohol 
Wittig reaction is one of the common reactions known for replacing the carbonyl group (C=O) 
with an alkene group (C=C). In general, the reaction is based on the nucleophilic attack on the 
carbonyl group (electrophile) by the carbanion part of the phosphonium ylid.  
Consequently, negative charge on the aldehydic oxygen is formed. The negative charge will 
attack the phosphorus positive charge, giving rise to four membered ring transition state called 
oxaphosphetane, which cleaves forming the desired alkene with triphenylphosphine oxide as 
by product (scheme 8). The phosphonium ylid is originally formed from the deprotonation of 
the phosphonium salt, which can be readily synthesized in a reaction between triphenyl 
phosphine and an alkyl halide. Opening the acetal is required to reveal the carbonyl group. This 





proton from the benzoic acid, forming a positive charge on the oxygen. This will push the lone 
pair of the alcoholic oxygen to make a resonance movement in order to open the pyran ring. 
The alcohol will be in one side and the aldehyde group on the other after removal of the proton. 
At this stage the Wittig reaction could proceed. The stereo chemistry of the resulted alkene 
depends on whether the ylid is stabilized or not. In case of a stabilized ylid by the presence of 
adjacent carbonyl group, gives the E alkene selectively. On the other hand, the unstabilized ylid 
forms the Z alkene selectively [135,136]. Wittig reaction is widely applied for many synthetical 
uses [137,138].  
Mechanism  
 






1.4.1.3 Reduction of the alkene. 
 
Scheme 9. Reduction of the alcohol`s bi bond 
A Pd/C-catalyzed hydrogenation is one of the most common C-C double and triple bond 
reduction reactions. This method of hydrogenation based on the absorption of the H2 on the 
surface of the metal catalyst. The H-H bond cleaves, each hydrogen attaches to the metal 
catalyst surface, forming metal-hydrogen bonds. In addition, the alkene itself will be absorbed 
on the surface of the metal catalyst. At this stage, one of the hydrogen atoms will transfers to 
the alkene forming a new C-H bond. The other hydrogen atom will transfer to the alkene 
forming another C-H as well, with the other carbon of the c-c double bond.  According to the 
physical arrangement of the alkene and the hydrogen on the flat surface of the metal catalyst, 
the two hydrogen atoms pictured to be added as syn addition. It means that they both come 
on the same phase or the same side of the alkene [139, 140]. This metal catalyzed 
hydrogenation have been widely applied in many industrial and research work [141]. It is also 
used in the food industry to make a large variety of manufactured goods [142].  
Mechanism 
 





1.4.1.4 Parikh-doering oxidation  
 
Scheme 10. Parikh-Doering oxidation of the 1° alcohol 
Parikh- Doering reaction provides a mild oxidation method for primary and secondary alcohols 
to aldehyde and ketones respectively. This method is based on using DMSO as an oxidizing 
agent after being activated by sulphur trioxide pyridine complex in the presence of a base, 
which commonly is triethyl ether. This reaction is performed under mild conditions. The 
temperature of the reaction varies from 0°C to room temperature. DMSO exists in two-
resonance structure it reacts with the Sulfur trioxide in its counter ion structure forming an 
intermediate. The lone pair of the hydroxyl group will attack this intermediate. The pyridine will 
then deprotonate the alcohol forming an alkoxysulfonium ion associated with the anionic 
pyridinium sulfate complex. The base deprotonates the alkoxysulfonium ion providing the 
sulfur ylid and the pyridiniuim sulphate counterion. This sulfur ylid goes through a five 
membered ring transition state before it breaks and provide the desired aldehyde or ketone 
according to the used alcohol type and dimethyl sulfide as a byproduct. This reaction has been 
used widely in many applications [144]. 
Mechanism  
 





1.4.2  Preparing of the Wittig salts  
1.4.2.1 Friedel-Crafts acylation  
 
Scheme 12 . Synthesis of the acylated toluene 
The reaction is a regular Friedel-Crafts acylation between toluene and heptanoyl chloride.  The 
acylation term refers to the direct formation of compounds containing carbonyl group and 
attached to the aromatic system. Moreover, the formation of ketones, aldehydes, carboxylic 
acids, and amides [145]. The aluminum chloride removes chloride from the heptanoyl chloride 
forming a cation, this cation is a linear acylium ion. This linear ion is stabilized by the adjacent 
oxygen lone pairs. The acylium ion attacks the benzene ring at ortho and para position because 
of the CH3 which acting as e.donating group and activate o, p positions of the benzene ring 
giving the desired aromatic ketone. Both fridel kraft acylation and alkylation reactions have 
been widely used in many applications for long time. For example, the acylation of polycyclic 
aromatic hydrocarbons such as naphthalene and anthracene [146]. 
Mechanism 
 






1.4.2.2 Benzylic bromination “visible light approach” 
 
Scheme 14. Benzylic bromination of the acylated toluene 
The reaction is a benzylic bromonation induced by visible light. It is a high regioselective 
halogenation of the alkyl benzene by using N-bromosuccinimide (NBS) in presence of light. It is 
considered as the greener version of the Wohl- Ziegler bromination. In addition to the simple 
isolation protocol as the only byproduct is the succinimide, which is soluble in water.The 
benzylic bromination reaction could be performed using thermal energy instead of light and in 
presence of radical initiator as benzoyl peroxide. This reaction allows the bromination to be 
specifically on the allylic position of an alkene. In this case, the bromination occur on the 
benzylic position of the alkyl benzene due to the stability afforded to the radical by means of 
resonance [147]. Free radical formation by the homogenous cleavage of the N-Br bond was 
triggered because of the visible light Br free radical. The generated radical abstracts a hydrogen 
from the other molecule leaving a free radical in its place which will bind with another Br free 
radical forming the desired product. This reaction has been widely used in many regiospecific- 







Scheme 15. Mechanism of the benzylic bromination using NBS in visible light. 
1.4.2.3 Wittig salts from alkyl halides and triphenylphosphine 
 





This reaction is a simple nucleophilic substitution reaction. The high-energy lone pair of the 
phosphorus in the triphenylphosphine reagent attacks on the electrophilic alkyl halide resulting 
a new C-P bond in the desired tetrahedral phosphonium salt.  
 
Scheme 17. Nucleophilic attack by the triphenyl phosphine on the electrophilic carbon. 
Normally this salt undergoes deprotonation by some kind of base to produce the phosphonium 
ylid which is the nucleophilic partner in the Wittig reaction. Phosphonium salts are widely used 
in Solid Phase applications [149] and as co-catalysts in different cases [150]. 
Mechanism: 
 
Scheme 18. SN2 reaction mechanism 
1.4.2.4 The O-alkylation of the para cresol 
 
Scheme 19. O-alkylation of para cresol. 
This reaction is based on the formation of the phenolate anion. When the proton of the 
phenolic hydroxyl group is abstracted with a base. The anion reacts with the alkyl halide to 
alkylate the oxygen or carbons of the aromatic ring due to the possible resonance structures 





it is possible to get the C-alkylated product. In this case the hydroxyl of the phenol is 
deprotonated by the potassium carbonate base producing the phenolate anion.  
The character of aromaticity will be disturbed during the resonance to get the C-alkylated 
product. Therefore, the O-alkylation happens via a normal SN2 reaction between the anion and 
the alkyl halide. 
Mechanism 
 
Scheme 20. Benzylic o-alkylation mechanism “SN2” 
1.4.2.5  Benzylic bromination “Thermal Approach” 
 
 
                                                                   Scheme 21. Benzylic bromination. 
This reaction is another approach for the benzylic bromination by NBS under heating instead 
of the visible light in presence of benzoyl peroxide as radical initiator. The reaction is considered 
to have the same degree of regioselectivity as it was mentioned earlier in the visible light case 
(section 1.4.2.2). Free radical formation by the homogenous cleavage of the N-Br bond was 
triggered in this case because of the heat and benzoyl peroxide, which is the radical initiator. 
The Br free radical will abstract a hydrogen from the other molecule leaving a free radical in its 



















1.4.3 Wittig reaction  
Scheme 23. Wittig reaction of the ylid and the aldehyde. 
Wittig reaction is one of the premier methods for the alkene synthesis. It proceed through 
nucleophilic attack from the phosphorus ylid on the carbonyl group in the other compound. 
Elimination reactions (E1, E2) are common routes to alkene synthesis from alcohols or alkyl 
halides. In comparison to Wittig reaction, the carbon skeleton is pre-assembled in case of E1 or 
E2 within the molecule. Whereas Wittig allows a coupling of two fragments. Moreover, the 
elimination reactions give mixture of two isomers. In case of Wittig reaction there is no 
ambiguity about the position of the double bond. On the other hand, Wittig reaction can be 
compared to the aldol condensation where the carbonyl group attacked by an enolate instead 
of the phosphorus ylid. The phosphonium ylid produced when the phosphonium salt is 
deprotonated by the base KtBuO. The resulted carbanion is stabilized by the positive 
phosphorus in addition to the conjugation with the benzene ring. This anion is a strong 
nucleophile when it is formed, it attacks on the carbonyl group of the aldehyde forming an 
alkoxide. This group rapidly connects to the phosphorus forming a 4-membered ring that 
cleaves to the desired alkene and triphenylphosphine oxide as a byproduct [152].  Wittig 










Scheme 24. Mechanism of the Wittig reaction. 
1.4.4 De-protection of the acetonide                                                               
This reaction is the reverse of the acetonide formation reaction. The 1, 2- diol system can be 
recovered by hydrolysis of the acetonide in aqueous acidic medium. There are many acids that 
could be used in this reaction such as acidic resins, acetic acid or acidic workup with 1N HCl. 
One of the acetonide oxygens will be protonated by the acidic medium, forming an oxonium 
ion making itself a good leaving group. The other oxygen of the acetonide will attack the 
electron deficient carbon through its lone pair, which will liberate one hydroxyl group. An 
unstable oxonium ion will be formed on the other side. The oxonium ion is a powerful 






 Proton exchange between the solvent and the etheric oxygen will lead to another oxonium ion 
formation. The alcoholic lone pair will attack on the electron deficient carbon leading to a C-O 
cleavage recovering the 1, 2 diol system and producing acetone as by product [155, 156].    
Mechanism     
 
Scheme 25. Deprotection of the diol in acidic medium. 
1.4.5 Reduction of benzylic ketone  
This reaction is a nucleophilic attack by a hydride on a carbonyl group. Sodium borohydride is 
the source of the hydride. The nucleophile is the hydrogen atom carrying the pair of electrons 
from the B-H bond. This hydrogen atom will be transferred to the carbonyl in a nucleohilic 
attack. The reaction runs in protic solvents such as water and alcohols. These solvents are 
necessary for the protonation of the alkoxide to give the desired alcohol as a result of the 
reduction process [157]. 
 





The mechanism proceeds in two steps. In the first step, the hydrogen with the lone pair 
detaches from the BH4 and adds to the carbonyl carbon in a 1, 2 addition forming C-H bond, 
and breaks the C-O bond forming an alkoxide.  In the second step, a proton from water or the 
protic solvent is added to the alkoxide to form the alcohol [158].  
 
Scheme 27. Carbonyl group reduction mechanism. 
1.4.6 Lactone formation 
Lactones are internal hydroxycarboxylic acids and esters. They are formed by intramolecular 
esterification from their corresponding linear forms. The ease of formation depends on the size 
of the formed ring, it is more likely in case of 5 or 6 membered rings. Those of small ring size or 
bigger than 6 membered ring are hard to isolate due to their high reactivity [159,160]. In this 
case the lactone ring is rapidly formed after the deprotection of the diol (Scheme25). The 
reaction starts in acidic medium when protonation of the carbonyl oxygen take place, which 
will make the carbonyl group more electron deficient. This will lead the hydroxyl lone pair to 
attack on the electronegative carbonyl group forming the six membered ring. A proton transfer 
process followed by loss of the ethanol fraction furnishing the six membered ring lactone 












Scheme 28. Lactone formation mechanism. 
1.4.7 Ullmann approach 
There are two classes of Ullmann reactions. The “classic Ullmann reaction” catalyzed by Cu 
refers to the synthesis of symmetric biaryls through the copper-catalyzed coupling (Scheme 
29). The biaryl is accessible through coupling of the aryl halide in excess of the Cu at high 
temperature (150-200C). The mechanism includes oxidative addition with a second equivalent 
of the aryl halide followed by reductive elimination to furnish the desired biaryl. This class of 
Ullmann reaction has been applied in some studies. The Immobilization of Copper (II) in 
Organic-Inorganic Hybrid Materials as a Highly Efficient and Reusable Catalyst for the Classic 
Ullmann Reaction was reported [161].  
 
Scheme 29. Classic Ullman reaction 
The other class “Ullmann type” reaction refers to copper – catalyzed nucleophilic aromatic 






Scheme 30. “Ullmann Type” reaction 
This class of Ullmann reaction proceed through a catalytic mechanism (Scheme 31). This type 
is mostly used in Ullmann ether synthesis as it is conducted in our case. Altman et al. reported, 
the use of this approach to provide an Improved “Cu-Based Catalyst System” for the Reactions 
of Alcohols with Aryl Halides. In addition, they claimed the improvement of the reaction in 
presence of a ligands. As a result it reduces the excess of the alcohol needed for the original 
reaction to proceed and support milder condition for the reaction [175]. Moreover, Ajay B. 
Naidu et al. postulated a general, mild, and intermolecular ” Ullmann-Type” synthesis of diaryl 
and alkyl aryl ethers catalyzed by diol−copper(I) Complex [162]. Cristau et al. suggested a 
general and mild Ullmann-type synthesis of diaryl ethers as applications on the Ullmann type 
reaction [163].  
Mechanism  
 

































2 RESULT AND DISCUSSION 
2.1 THE SCOPE OF THE CHAPTER 
This chapter describes my contribution towards the synthesis of LXA4 analogues (Scheme 32). 
It introduces earlier studies in the same field of interest. In addition, discussing results within 
the performed reaction sequence. Lactone formation (section 2.13, 2.14) is considered to be 
an interesting intermediate that resulted from the deprotection of the diol 14, 15 (section 2.12, 
2.14). In a later stage of this chapter, we reported a computational study that explain the 
formation of these intermediates. Moreover, it support the actual mechanism based on the 
change in free enrgy values (∆G) of each step (section 2.17). 
 
 












2.2 PROTECTION OF 2-DEOXY-D RIBOSE 
 
Scheme 33. Synthesis of the protected sugar 
Klimko et al. reported, the use of 2-methoxypropene as the reactant in the transformation from 
2-deoxy-D-ribose to the acetal 2 with PPTS in ethyl acetate [164]. In addition, Colm Duffy and 
Philips ED reported the same treatment of the sugar at room temperature resulting the product 
2 in 43% yield [165,166]. K. C. Nicolaou reported the use of Me2C(OMe)2,p-TsOH (cat) in 
acetone for the protection of same moiety with 87% yield [167]. The conducted treatment in 
this research is based on the earlier studies [165]. Where the observation showed insolubility 
of the sugar in ethyl acetate and its selectivity towards some organic solvents. Using DMF 
solvent showed good solubility of the sugar at room temperature and even at lower 
temperature. The reaction was performed in very dry conditions and with the use of molecular 
sieves to capture the water. The crude consisted of the desired product and the methylated 
alcohol as by product, which could be separated using column chromatography affording 41% 
pure product 2 which is invisible under UV light. The success of the reaction was confirmed by 
mass spectrometry. The new two singlets peaks in the 1H-NMR spectra 1.35(s, 3H), 1.22(s, 3H) 










2.3 SYNTHESIS OF THE ALKENE FROM THE SUGAR 
 
Scheme 34. Synthesis of the alkene via Wittig reaction. 
 Colm Duffy, Klimko, and Philips ED. reported the same treatment of the aldehyde with refluxing 
in THF resulting 81% of alcohol 3 [164-166]. The reaction conducted in this project based on 
the earlier studies with minor modifications. The protected sugar 2 treated with the 
commercially available Wittig salt (1:1.5) mol equivalency respectively in toluene furnished 
alcohol 3 in 87% yield. The crude contained a big excess of the salt which appeared with the 
same Rf value as it contain same kind of groups. In this case the crude had to be washed with 
diethyl ether that showed a good solubility of the product unlick the excess reactant which 
precipitate in such solvent. The resulted oil submitted for further purification by means of 
column chromatography furnished a pure colorless oil of compound 2 in 87% yield. The 
reaction was tested with (1:1) equivalent that gave 80% yield of the alcohol.  The success of the 
reaction confirmed by mass spectrometry and NMR. The visibility of the product under UV light 
due to the new formed double bond also gives indication on the formation of the alkene. The 
new two characteristic signals of the double bond and the ester group in the 1H-NMR spectra 
clearly indicate the formation of the alkene, 6.97-6.90 (m,1H), 5.89 (d, J=16 Hz, 1H),  4.20-








2.4 REDUCTION OF THE ALKENE. 
 
Scheme 35 synthesis of the reduced alcohol. 
Adile Duymaz reported the same reduction method for the alkene 3 in MeOH furnished 83% 
the reduced alcohol 4 [168]. Moreover, Klimko reported the same treatment in iso-propanol 
[164]. Colm Duffy, and Philips ED et al. reported the catalytic hydrogenation using 10% Pd/C in 
ethanol furnished 87% yield of the reduced alcohol 4 [165,166]. The same treatment was 
conducted here in ethanol and gave 93% yield. The success of the reaction was confirmed by 
mass spectrometry beside the disappearance of the characteristic beaks of the double bond in 
addition to the invisibility of the product under UV light ( section 5.2.1.3).  
2.5 OXIDATION OF THE 1O ALCOHOL TO ALDEHYDE 
 
Scheme 36. Synthesis of the aldehyde. 
Swern oxidation was the first choice for many research approaches to achieve aldehydes from 
1o alcohols. Adile Duymaz, colm Duffy and Philips ED have reported the use of Swern type of 
oxidation to obtain the aldehyde 5 from the primary alcohol 4 with a yield ranges from 77% to 
86% [165,166, 168]. Parikh-Doering oxidation is another type of oxidation which was conducted 





conditions from 0oC to r.t without formation of very odorous volatile by-products such 
as dimethyl sulfide and carbon monoxide as in Swern oxidation.  
Purification trials by means of automated flash chromatography and column chromatography 
failed as the product gets lost on the silica. The crude was forward used without further 
purification. The success of the reaction was confirmed by mass spectrometry and NMR. The 
new 1H-NMR signal of the aldehydic hydrogen appears at 9.56 (s, 1H). In addition to, the 
visibility of the aldehyde under UV light (section 5.2.1.4).  
2.6 FRIEDEL-CRAFT ACYLATION OF THE TOLUENE      
 
Scheme 37. Synthesis of the acylated toluene 
Friedel craft acylation reaction was assembled by using the commercially available toluene, acyl 
chloride and aluminum chloride in DCM furnished 73% yield of pure product 7. The success of 
the reaction was confirmed by 13C-NMR and the new characteristic beaks in 1H-NMR 2.92 (t, 
2H), 2.40 (s, 3H), 0.88 (t, 3H) (section 5.2.2.1.1). 
2.7 BENZYLIC BROMINATION OF THE ACYLATED TOLUENE. 
 
Scheme 38. Synthesis of the brominated acyl. 
Ajda Podgorsek et al. reported, the benzylic bromination of various 4-substituted toluenes 





initiator of the radical chain process gave 86% yield of bromo-benzylic toluene derivatives 
[169]. The bromination of the previously synthesized para acylated toluene 7 was conducted 
following the same princible using NBS, (TFT/ water) as the solvent mixture and illuminated 
with a 60 W incandescent light bulb at room temperature resulted 83% yield of the mono-
brominated product 8. The success of the reaction was confirmed by 13C NMR and the new 
characteristic signal of the brominated benzylic –CH2 1H-NMR 4.51 (s, 2H), (section 5.2.2.1.2). 
2.8 WITTIG SALT FROM THE BENZYL BROMINATED TOLUENE DERIVATIVE 
 
Scheme 39. Synthesis of the Wittig salt. 
The Wittig salt 9 was conducted with refluxing triphenylphosphine and the previously 
synthesized compound 8 in acetone for 3-5hr at 65oC resulted 82 % yield. The success of the 
reaction was confirmed by Mass Spectrometry, IR, and NMR.  The new characteristic doublet 
appeared in the 1H-MNR with the significant J coupling to the phosphorus at 5.64 (d, J= 16 Hz, 
2H) clearly indicate the formation of the Wittig salt 9, (section 5.2.2.1.3). 
2.9 PREPARATION OF THE O-ALKYLATED P-CRESOL 
     
              Scheme 40. Synthesis of the benzylic ether 
Milhanic  et al. reported the success of the O-alkylation of the p-cresol refluxing for 48h in 
acetonitrile with potassium carbonate gave 88% yield of the ether 11 [170]. In addition, Hong-
Cheu Lin et al. reported the same treatment with refluxing for 24 h in a mixture of 





ether 11 [171]. Both methods were applied in this project. The reaction was successful in both 
treatments with a yield ranges from 72%-76% (Table 2). The product was pure and used in the 
next reaction without further purification. The success of the reaction was confirmed by the 
mass spectrometry and NMR.The characteristic beaks in 1H-NMR of the O-CH2 and the para 
benzylic methyl group 3.95 (t, 2H), 2.32 (s, 3H), respectively clearly indicated the formation of 
the desired product (section 5.2.2.2.1).                                                          
2.10  BENZYLIC BROMINATION OF THE ETHER  
 
Scheme 41.Synthesis of the brominated benzylic ether. 
Bromination of the benzylic ether 11 was reported in earlier studies. The reaction took place 
by refluxing benzylic ether 11 in carbon tetrachloride with NBS and a catalytic amount of 
dibenzoyl peroxide resulted 36% yield of the desired product [170]. The reaction was 
performed based on this study, gave 48% yield of the mono-brominated benzylic alkyl 12. The 
observation showed the high possibility of producing mixture of the mono and the di-benzylic 
brominated products. This problem was indicated by the integration difference of the 
representing signal of the brominated alkyl in 1H-NMR. The degree of bromination found to be 
dependent on the mol equivalency of the starting material 11 to the NBS, and the reaction time 
(Table 1). The success of the reaction was confirmed by NMR. The new beak appeared in the 










Table 1. Reaction optimization towards the bromination of the benzylic ether 
Trial Solvent Reaction 
time 
Equivalency 
( cpd 11: NBS) 
Yield% product 
1 CHCL3 9h (3*3) 1:3 19 % Dibromo 
2 CHCL3 9h (3*3) 3:1 83 % mixture 
3 DCM 6h (2*3) 3:1 48% monobromo 
                          
2.11  WITTIG SALT FROM THE BROMO-BENZYLIC ETHER  
 
Scheme 42. Synthesis of the Wittig salt of the benzylic ether 
Earlier studies suggested the preparation of the Wittig salt by refluxing the bromide compound 
12 in xylene and toluene with triphenyl phosphine for 18h furnished yield ranges from 88% to 
69% respectively [170,171]. Based on these studies the reaction was tested in the same solvent 
systems unsuccessfully. This could be related to instability of the compound in high 
temperatures or unsuitable reaction conditions.  Another mild temperature conditions was 
conducted in this project. Refluxing the reaction mixture in acetone for shorter time gave 72% 
yield of the Wittig salt 13. The success of the reaction was confirmed by mass spectrometry, IR, 
and NMR. The new characteristic doublet appeared in the 1H-MNR with the significant J 
coupling to the phosphorus at 5.23 (d, J=16 Hz, 2H) clearly indicate the formation of the Wittig 






2.12  WITTIG REACTION OF THE ALDEHYDE AND THE KETONIC WITTIG SALT 
 
Scheme 43. Synthesis of the coupled alkene 
Wittig reaction was a successful approach to obtain the desired product 15 from the Wittig salt 
9 and its aldehyde partner 5 in 47%. The reaction should be preceded under very dry conditions 
and in dry solvents. The success of the reaction was confirmed by mass spectrometry, IR, and 
NMR. The new characteristic beaks appeared in the 1H-NMR such as the beak at 6.74 (d, J= 8 
Hz, 1H) and 5.83 (t, 1H) for the new trans double bond resulted from the Wittig coupling. Similar 
target compounds were assembled by other approaches in different researches [172], (section 
5.2.3) .  
2.13  HYDROLYSIS OF THE ACETAL IN THE KETONIC MOIETY CONTAINING PRODUCT 
     
                                           Scheme 44. Hydrolysis of the acetal in the ketone containing compound 
The reaction targeted the deprotection of the diol moiety in compound 15.  The lactone 
formation is commonly reported in many researches that had to deal with such cases. The main 
theme of these compounds is groups as alcohols or diols and ester or carboxylic acid group in 
the same side of the compound. The reason behind this could be due to the reactivity of the 
hydroxyl group in addition to the stability of the six membered ring of the formed lactone. The 
fact that this lactone formation is an intramolecular reaction, further facilitate the formation. 
Computational study on the deprotection mechanism followed by the formation of the lactone 
ring has been conducted in this research in order to fully explain this case. Singh S et al. 
reported a one-pot esterification and deprotection of another 1, 2- diol system using ZrCl4 that 





formation in similar case after deprotection of the same diol system using TBAF/THF gave 1:1 
yield percent mixture of the deprotected product and the lactone [165]. Pierre van de Weghe 
postulated similar case during the synthesis of Lipitor where the lactone group was assembled 
by the deprotection of the acetonid group with HCl in methanol and then treated with calcium 
acetate to furnish the desired product in a form of calcium salt [174]. Deprotection of the diol 
15 was conducted here using TFA in a solvent mixture MeCN/H2O (1:1) and furnished 70% of 
the lactone 16 .The lactone formation was confirmed by mass spectrometry, IR and NMR. The 
new characteristic beaks appeared in the 1H-NMR 4.40-4.36 (m, 1H), 2.87(t, 2H) indicate the 
formation of the lactone 16, (section 5.2.5).  
2.14  WITTIG REACTION OF THE ALDEHYDE AND THE ALDEHYDIC WITTIG SALT 
     
                                            Scheme 45. Synthesis of the coupled alkene of the benzylic ether 
The cross coupled product 14 was conducted in the same principle as in case of compound 15 
(section 2.12). Wittig reaction was assembled between the Wittig salt 13 and its aldehyde 
partner 5 and gave 30% of product 14. The success of the reaction was confirmed by Mass 
Spectroscopy, IR, and NMR. The new beaks that appeared in the 1H-NMR at 6.57 (d, J=12, 1H), 
5.54 (t, 1H) which represent the new trans double bond resulted from the Wittig coupling 
(section 5.2.4). 
2.15  HYDROLYSIS OF THE ACETAL IN THE ALDEHYDIC MOIETY CONTAINING PRODUCT 
 
Scheme 46. Hydrolysis of the acetal in the ether containing compound 
According to the same principles discussed in case of compound 16 it was expected to follow 





solvent mixture of MeCN/H2O (1:1) at room temperature for 1h. The mass spectroscopy 
showed the absence of the molecular mass of the expected product. 
 While the desired compound 17 was assembled using 1N HCl in THF overnight furnished 70% 
yield. The success of the reaction was confirmed by Mass Spectroscopy, IR (section 5.2.6). 
2.16  ULLMANN APPROACH 
2.16.1  Preparing the O-alkylated phenol derivative. 
 
 
Scheme 47. Synthesis of the O-alkylated phenol 
Compound 20 was conducted according to the same principle used to achieve the benzylic 
ether 11 (section 2.9). The compound was assembled by the treatment of 4-bromophenol with 
1-bromo hexane and potassium carbonate under refluxing for 24h. It furnished the desired 
product 20 in 85% yield. The success of the reaction was confirmed by the Mass Spectrometry 
and NMR. The new characteristic signals appeared in the 1H-NMR at 3.96 (t, 2H), and 0.96 (t, 
3H) clearly indicate the formation of the desired product 20, (section 5.2.7.1).  
2.16.2  Preparing the Ullmann ether 
 
Scheme 48. Synthesis of the Ullmann ether 
Ryan A. Altman postulated, the use of 3, 4, 7, and 8-tetramethyl-1, 10-phenanthroline as a 
ligand to improve the Cu-catalyzed cross coupling of alcohols with aryl halides (iodides and 





and cesium carbonate in toluene at 80-110 oC for 9-24h to give the cross coupled product in 75 
% yield. The same treatment has been applied on the aryl halide 20 and the alcohol 4, but 
resulted no reaction (Table 2). The reaction was tested by using 1:2 equivalent of the aryl halide 
and the alcohol respectively, 5% of the catalyst (bis-bipyridyl ligand modified complex), and 
K3PO4 under argon at 110 oC for 24-48 h furnished 61-91% yield.  
The reaction could be further optimized for successful reaction conditions. Another reaction 
system was suggested by Jiajia Niu et al. that could be useful to test, as an efficient O-arylation 
of aliphatic alcohols with aryl halides using an air-stable copper (I) complex as the catalyst 
[176],(section 5.2.7.2).   
Table 2. Initial optimizations of Ullmann reaction conditions. 
Trial ligand % Catalyst 
% 
method Aryl halide: Alcohol Time Yield % 
1 10 5 Normal 
heating 
1:1.5 2h - 
2 10 5 mw 1:1.5 2h - 
















2.17  A TOTAL COMPUTATIONAL STUDY ON THE LACTONE CASE 
2.17.1  Density functional theory (DFT) calculations  
 Computational Details 
 The quantum chemical calculations have been performed using the Gaussian Quantum 
chemistry program [176]. All the geometries of the molecules studied were optimized using 
the B3LYP functional [177-179]. The 6-311G (d, p) basis set was used for the optimizations and 
frequency calculations [180]. All the thermodynamic property calculations were performed at 
298.15K and 1.00 atm. Solvent effects were corrected by using the polarizable continuum 
model (PCM) in its integral equation formalism (IEF) and acetonitrile as a solvent to mimic the 
experimental conditions [181].  
2.17.2  Discussion of the calculated results 
The proposed reaction mechanism for the lactone formation based on the DFT calculations is 
shown in (Figure 12). The change in the standard Gibbs free energy (in kcal/mol) and change in 
entropy (in cal/mol.K), through each step of the mechanism, gives indication on the spontaneity 
of the reaction. In addition, it shows to how much extent the reaction is favorable to proceed 
in the specific direction towards the product, see (Figure 12). 
The study on the free energy and the entropy of the reaction showed that the reaction most 
likely proceed towards the formation of the most stable product that shows the lowest ∆G 
value, which is the 6-memberd ring lactone. The first step which presents the protonation of 
the acetonide moiety showed spontaneous activity towards the formation of the protonated 
product 2 with ∆G = -4.2 kcal/mol and ∆S = -1.6 cal/mol.K. While the reaction progresses 
towards the formation of the oxonium ion intermediate 3 from the intermediate 2 showed also 
favorable step with ∆G = -1.4 kcal/mol and ∆S = +1.72 cal/mol.K. Then, with the nucleophilic 
attack on the oxonium ion intermediate 3 by the water molecule the reaction proceed towards 
the formation of intermediate 4 with ∆G = -1.5 kcal/mol and ∆S = -24.3 cal/mol.K. On the other 
hand, the proton exchange between the water molecule and the oxygen of the protected 
hydroxyl towards the formation of intermediate 5 showed ∆G = +0.5 kcal/mol and ∆S = -2.9 





Overall, the free energies through intermediates 3-5 supports that the flow of the mechanism 
through these intermediates is favorable towards intermediate 5 with ∆G = -1.0 kcal/mol and 
∆S = -27.2 cal/mol.K. 
 
 
Figure 12. Courtesy of Dr. Taye B. Demissie .B3LYP/6-311G (d, p) calculated change in standard Gibbs free energy (kcal/mol) 








Losing the water molecule in a resonance movement towards the formation of product 6 
showed ∆G = +14.9 kcal/mol and ∆S = +33.4 cal/mol.K, which may look unfavorable reaction. 
However, the parallel reaction mechanism for retaining the TFA acid from the anionic TFA and 
the protonated acetone shows ∆G = -54.8 kcal/mol and ∆S = +8.5 cal/mol.K, which controls the 
overall reaction at this step and the result would be in favor of proceeding the mechanism 
towards the formation of product 6 with a net ∆G = -39.9 kcal/mol and ∆S= +41.9 cal/mol.K. 
Due to the presence of acid in the reaction medium “acidic medium”, the carbonyl group in 
product 6 is easily protonated to form intermediate 7 in a favorable reaction with ∆G = -4.3 
kcal/mol and ∆S = -4.7 cal/mol.K. The overall energetics for the last step, the mechanism 
proceeds in a favorable manner towards the formation of the six member ring lactone in 
addition to the loos of ethanol molecule plus retaining of the acid catalyst with ∆G = -39.3 
kcal/mol and ∆S = +41.9 cal/mol.K. 
The last mechanism for the formation of the six member ring lactone is further analyzed based 
on the potential energy surface (PES) shown in (Figure 13).  The PES for the internal cyclization 
of compound 6 leading to the formation of compound 8 is another explanation element on the 
preference of lactone formation rather than the corresponding linear ester. In addition, the 
possible cyclization reaction with and without the protonation of the carbonyl group are also 
compared in (Figure 13). The (a) model shows that the cyclization reaction do not proceed for 
the unprotonated carbonyl group, where it shows increase in the energy as the hydroxyl oxygen 
and the carbonyl carbon  distance decreases referring to the instability of the compound with 
the decrease in the distance. The (b) model shows that the cyclization of compound 7 which 
has a protonated carbonyl group. The PES clearly shows the favored formation of the six 
member lactone if the carbonyl group is protonated. This also refers to the essentiality of the 








Figure 13. Courtesy of Dr. Taye B. Demissie .Potential energy surface (PES) for the cyclization of compound 6 leading to the 
formation of compound 8: a) shows the cyclization without protonation of the C=O of the ester group, whereas b) shows the 






3 FUTURE DIRECTIONS 
According to previous studies based on the structure activity relationship of LXA4, wide range 
of modification and functionalization interest was brought on the way of the research delivered 
in this thesis. There are two pathways of structure modification of LXA4 .These pathways aims 
at the replacement of some functionalities in the native LXA4 with other chemical stable 
functionalities in order to retain the potent biological activity. The first pathway is based on the 
triene moiety to be involved in a stable aromatic, heteroaromatic and the substituted fused 
benzo systems, see pathway 1 (Scheme 49). Which play an important role of prevention of the 
reduction at C13-C14 [166]. While the other pathway is based on the structure modification of 
the side chains at C15-20 and C1-8 , see pathway 2  (scheme 49). Which shows resistance to the 
oxidation at C20 and prevention of the β oxidation respectively [166, 183, 184]. Through 
different and wide range of organic synthesis reactions including photochemistry could provide 
methods for the possible late stage functionalization and modification of the already prepared 
analogues. Moreover, it could participate in expanding the library of LXA4 analogues that might 






Scheme 49. Strategies for structural diversity of LXA4 analogues library 
The late stage functionalization is based on the wide range of the function groups that could 
be inserted or replaced in the already synthesized analogues. These new structural features 
would provide a library of the LXA4 analogues to be scanned for biological activity. Some of 
these novel function groups could participate on enhancing the biological properties of the 
analogues. Some of these groups have already shown some biological potentialities. For 
examples the para- fluorophenoxy analogues showed extreme potency for inhibiting the tumor 
necrosis factor (TNF)-α-induced leukocyte recruitment into the dorsal air pouch. Moreover, it 
has shown some potentials as anti–cancer agents [185]. All of these ideas could be executed 







Scheme 50. Late stage functionalization strategy 
A diversity of synthetic tactics could be developed and applied in order to assemble new stable 
LXA4 analogues that could be interesting from chemical and biological point of view.  
 
































4 SUMMARY AND CONCLUSIONS 
This section describes the synthesis of compounds 16 and 17 through multiple steps. Starting 
from the commercially available 2-deoxy-D-ribose, toluene, and p-cresol, the desired products 
were assembled within 14 steps. An overview of the performed reactions with the obtained 
yields for every intermediate is reported (Scheme 52). 
 
Scheme 52. Summary of  Reagents and conditions.(1) 2-methoxy propene, PPTS, acetone at 0C; (II)Ph3PCHCO2Me, Toluene at 
90C ; (III)H2 /Pd, EtOAc; (IV)SO3-Pyr NEt3 , DCM at 0C to rt; (V)Acyl chloride, ALCl3, under N2 gas at 0C with stirring; 
(VI)NBS,H2O/ trifluoromethyl benzene, h for 27 h at rt; (VII)PPh3 ,acetone, reflux for 3h at 65C; (VIII)Wittig reaction under very 
dry conditions ,THF, Potassium tert-butoxide at 0C to rt, stirring for 2h under N2 gas; (IX) TFA, MeCN/H2O, 1:1 ;(X) NaBH4, 
MeOH, 1h at r.t; (XI,XII) 4M NaOH, MeOH, 1h at r.t; (XIII)1-Bromohexane, K2CO3, acetonitrile , protected under N2 gas, refluxed 
at 85C for 24 h; (XIV)NBS,Bz2O2, CHCl3 reflux at 68C ; (XV) PPh3, acetone, reflux for 3h at 65C; (XVI) Wittig reaction under 





Our results concerning the total synthesis towards LXA4 analogues reflect the diversity of 
compounds and synthetic tactics which could participate in expanding the synthetic library of 
LXA4 analogues. 
Chapter “1” included the goals and strategy of the thesis in addition to the retro-synthesis study 
Moreover, the biological background of the targeted pharmacological agent. Followed by the 
forward synthesis and theoretical chemical background of the performed reactions. 
The first practical part in this thesis (chapter 2) describes my efforts towards the total synthesis 
of substituted ρ- benzoid LXA4 analogues. The synthesis of the late stage intermediates 16 and 
17 was successfully assembled within 14 steps from the commercially available starting 
materials 2-deoxy-D-ribose, toluene and p-cresol in 70% yield. The total suggested strategy was 
successfully executed except the final lactone hydrolysis and the reduction of the benzylic 
ketone 16. 
Chapter 3 gives some novel ideas about late stage functionalization of the already prepared 
analogues.  In addition, suggesting new structure that could be interesting stable analogues of 
LXA4 as future directions. 
According to the computational study performed on the lactone formation mechanism, we can 
conclude that the lactone product should be the expected product from the acetonid hydrolysis 
step. In addition, Potential energy surface (PES) confirmed that protonation on the carbonyl 
group could be the driving force for the mechanism to proceed towards the favorable direction 
of the lactone cyclization. 
 







Figure 15. Optimized structure of compound 17, see Figure 12. 
Further work on this project could be ongoing. Priority is to complete the total synthesis by the 
hydrolysis of the lactone moiety in compound 16 and 17. In addition, optimizing the new 
Ullmann coupling towards successful conditions. Moreover, submitting the synthesized 














































5 EXPERIMENTAL SECTION 
5.1  GENERAL EXPERIMINTAL CONSIDERATIONS 
All reactions were carried out under an inert atmosphere of nitrogen using oven dried 
glassware. All solvents and reagents were purchased commercially from sigma-Aldrich and 
were utilized without further purification unless specifically noted. Dry solvents were obtained 
from a sodium/benzophenone still, from water free bottles or dried over molecular sieves 
before use. Flash chromatography was carried out using silica gel 35-70 micron from DAVISIL. 
Evaporation in vacuo refers to the removal of volatiles on a Büchi rotary evaporator with an 
integrated vacuum pump. Thin-layer chromatography (TLC) was performed on Merc KGaA, 60 
F254 silica gel plates and visualized with UV ans stains. Microwave reactions were carried out 
using microwave synthesis reactor, monowave 300 from Anton Paar.  
NMR spectra were recorded on Varian Mercury-400 Oxford NMR Spectrometers and Oxford 
NMR 400 MHz and 400 MHz Bruker Avance III HD equipped with a 5 mm SmartProbe BB/1H, 
using CDCl3 as the solvent. The reference values used for deuterated chloroform (CDCl3) were 
7.26 and 77.02 ppm for 1H and 13C-NMR spectra, respectively. Deuterated DMSO (DMSO-d6) 
reference values were 2.5 and 39.51 ppm for 1H and 13C-NMR spectra, respectively. Chemical 
shift values (δ) are reported in parts per million (ppm) commensurate to tetramethylsilane 
(TMS) as standard. Multiplicities are indicated as s (singlet), d (doublet), t (triplet), q (quartet), 
p (pentet), m (multiplet), bs (broad singlet) and coupling constant J were reported in Hz. 
 All NMR spectra were processed with MestReNova v7.1.1.1. Some 13C-NMR spectra from the 
early model studies have artifacts in a repeating pattern originated from unknown transmitter. 
Some 1H-NMR spectra may contain some of remaining solvents, mainly EtOAc. Infrared spectra 
were recorded on a Varian 700e FT-IR spectrometer and bands are reported in wavenumber 
(cm-1).High resolution MS was recorded on a thermos electron LTQ Orbitrap XL +Electrospray 
ion source (ION/MAX) using methanol as solvent. The melting points was measured with Buchi 







5.2 DETAILED EXPERIMENTAL PROCEDURES AND CHARACTERIZATIONS  
5.2.1 Synthesis of the aldehyde  
 
5.2.1.1 Synthesis of the protected 2-deoxy-D-ribose 
 
 
The commercially available 2-deoxy-D-ribose 1 (3 g, 22.36 mmol) was dissolved in 10ml DMF in 
a dry and clean round bottomed flask equipped with molecular sieves and stir bar. The mixture 
stirred under N2 gas at 0C before 2-Methoxypropene (3.225 g, 44.72 mmol) was slowly added 
to it. In another flask, a solution of pyridinium p-toluenesulfonate (0.50 g, 20.12 mmol) in 
minimum amount of DMF was stirring for 5 min before addition to the reaction mixture at 0C. 
The reaction continued stirring at 0C for 3h, then it was left overnight at room temperature. 
The product was filtered by suction and washed several times with DMF then dried in a high 
pressure pump.  The crude was purified by means of column chromatography (pentane/ethyl 
acetate, 1:1) affording a colorless oily liquid (1.751 g, 41 %) of the protected sugar 2. TLC; Rf=0.2 
(heptane/ethyl acetate, 1:1); HRMS (ESI) m/z: [M+Na]+ Calcd. for  C8H14O4Na 197.08, found 
197.0800 and [M+MeOH]+ 299.1000; 1H-NMR (DMSO-d6, 400 MHz) δ =6.24 (d, J=8 Hz, 1H), 
4.95-4.91 (m,1H), 4.33 (dd, J= 4, 16 Hz, 1H), 4.04 (dd, J= 4, 16 Hz, 1H), 3.77 (dd, J=  4, 16Hz, 1H), 





;13C-NMR (DMSO-d6, 100 MHz) δ=108.0, 90.4, 71.3, 70.7, 61.6, 33.2, 27.8, 25.9. The data is 
consistent with literature [166, 185]. Appenix 1. 
5.2.1.2 Synthesis of the unsaturated alcohol from the protected sugar  
 
The protected sugar 2 (0.787, 4.51mmmol) was dissolved in 10 ml toluene and left under reflux 
with stirring until it reaches 90 C. Benzoic acid ( 0.0276, 0.226 mmol) was added to the reaction 
mixture followed by the slow addition of the Wittig salt solution in toluene to the reaction 
mixture at 90 C  . Reaction was refluxing for 2h and monitored by TLC.  Upon completion, the 
solvent was evaporated in a rotavap and the crude was washed with diethyl ether to remove 
the excess of the Wittig salt. The resulted oil was purified by means of column chromatography 
(pentane/ ethyl acetate , 1:1) affording UV active  colorless oily liquid (0.96 g, 87%) of the alkene 
3 .TLC; Rf = 0.3 ; HRMS (ESI) m/z: [M+Na]+ Calcd. for C12H20O5Na 267.12 found 267.1200; 1H-
NMR (CDCl3, 400 MHz) δ =6.97-6.90 (m, 1H), 5.89 (d, J=16 Hz, 1H), 4.29-4.24 (m, 1H), 4.20-4.13 
(m, 3H), 3.63 (d, J=8 Hz, 2H), 2.54-2.39 (m, 2H), 2.23(d, J=8, 1H), 1.45 (s, 3H), 1.34 (s, 3H), 1.25 
(t, J=8 Hz, 3H) ;13C-NMR (CDCl3, 100 MHz) δ=166.2, 144.5, 123.5, 108.4, 77.5, 75.3, 61.3, 60.3, 







5.2.1.3 Reduction of the alkene 
 
The previously prepared alkene 3 (0.568, 2.32 mmol) was dissolved in 10 ml ethyl acetate with 
10% pd/C. The reaction mixture was stirring at room temperature under H2 gas (1mp) for 5h. 
The rection progress was monitored by TLC. Upon completion the reaction mixture was filtered 
by suction on a Büchner funnel loaded with a celite cake to capture the catalyst. The filtrate 
was collected and the solvent was evaporated in a rotavap affording (0.55 g, 93%) UV inactive 
coloulress liquid of 4. TLC; Rf=0.3 (heptane/ethylacetate, 1:1); HRMS (ESI) m/z: [M+Na]+ Calcd. 
For C12H22O5Na 269.14 , found 269.1350; 1H-NMR (CDCl3, 400 MHz) δ = 4.09-4.04 (m, 5H), 3.54 
( d, J = 8 Hz, 2H), 2.29 (q, J= 4Hz, 2H), 2.09 (d, J= 8 Hz, 1H), 1.97 (s, 1H), 1.79-1.75 (m, 1H), 1.66-
1.61 (m, 1H), 1.55-1.51 (m, 2H), 1.39 (s, 3H), 1.29 (s, 1H), 1.18 (t, J= 8Hz, 4H);13C-NMR (CDCl3, 
100 MHz) δ=173.3, 108.1, 77.8, 61.6, 60.3, 33.9, 28.1, 25.4, 22.0, 14.2. The data is consistent 
with literature [166]. Appenix 3. 
5.2.1.4 Synthesis of the aldehyde  
 
The alcohol 4 (0.2 g, 0.8126) was dissolved in 10 ml DCM with stirring under N2 gas. (0.45g, 2.82 
mmol) of SO3-Pyr was added to the mixture and cooled down to 0C in an ice bath with stirring. 
Meanwhile, a solution of (0.40 g, 0.55 ml) triethylamine in 2.07 DMSO was stirring for 5 min 
before adding to the reaction mixture at 0C , 5 min after addition the ice bath was removed 





Reaction progress was monitored by TLC, product is UV active. After completion the reaction 
was quenched by 10 ml distilled water and stirred for 5 min before transferring into a 
separation funnel. After separation of the two phases. The aqueous phase extracted with DCM 
the organic phase concentrated in a rotavap. The crude was washed with water, sodium 
bicarbonate and brine, dried over Na2SO4, filtered and concentrated in a rotavap affording 
brownish orange liquid (1.73, 87%) ethyl 4-(5-formyl-2,2-dimethyl-1,3-dioxolan-4-yl)butanoate 
5. TLC; Rf=0.12 (heptane/ethylacetate, 4:1); HRMS (ESI) m/z: [M+Na]+ Calcd. For 
C12H20O5Na 267.12, found C12H20O5Na 267.1200 , and [M+MeOH]+  299.1460; 1H-NMR (CDCl3, 
400 MHz) δ =9.56 (s, 1H), 4.29-4.25 (m, 1H), 4.195 (dd, J= 4, 16 Hz, 1H), 4.05 (q, J= 8, 2H), 2.26 
( t, J= 8Hz, 2H), 1.77-1.73( m, 1H), 1.67-1.62 (m, 1H), 1.59-1.54 (m, 1H), 1.51 (s, 3H), 1.34 (s, 
3H),1.18 (t, J= 8 Hz, 3H); 13C-NMR (CDCl3, 100 MHz) δ= 201.9, 172.9, 110.4, 81.8, 78.1, 60.2, 
33.6, 29.0, 27.5, 25.2, 21.8, 14.1. Appenix 4. 
5.2.2 Synthesis of the Wittig salts     
5.2.2.1 Wittig salt of the ketone moiety containing compound  
 






Aluminum chloride (4.42 g, 33.18 mmol) was dissolved in 20 ml of dichloromethane while 
stirring in an ice path at 0C. Heptanoyl chloride (4.896 g, 32.94 mmol) was added dropwise to 
the reaction mixture followed by dropwise addition of toluene (2.73 g, 29.634 mmol).  
After addition, ice path was removed and the mixture continued stirring for 30 min at room 
temperature, the reaction was monitored by TLC. The reaction mixture was poured slowly with 
stirring into a baker contained 30 g of ice and 10 ml conc HCl, transferred into a separation 
funnel and extracted with ethyl acetate (2*30 ml) . The organic phase was collected and 
washed with saturated sodium bicarbonate (20 ml), brine (20 ml), dried over Na2SO4 then 
concentrated in rotavap. Crystals collected and purified by recrystallization in ethanol/water 
(5:1), filtered and dried in vacuuo affording white crystals of 7 (4.387 g, 73 %). m.p. : 35.5-36.8 
C. TLC; Rf = 0.8 (hexan/ethyl acetate, 9:1); 1H-NMR (CDCl3, 400 MHz) δ =7.85 (d, J = 8Hz, 2H), 
7.24 (d, J= 8 Hz, 2H), 2.92 (t, J = 8 Hz, 2H), 2.40 (s, 3H), 1.74-1.68 (m, 3H),  1.37-1.32 (m, 7H) , 
0.88 (t, J = 4 Hz, 3H) ;13C  NMR (CDCl3, 100 MHz) δ= 200.2, 143.5, 134.6 , 129.1 ,128.1, 38.5, 
31.6, 29.0, 24.4, 22.5 ,21.5, 14.0. The data is consistent with literature [187]. Appenix 5. 
5.2.2.1.2  Synthesis of benzylic brominated p- acylated toluene 
 
The previous synthesized acyl toluene 7 (3 g, 14.68 mmol) was dissolved in 12 ml of 
trifluorotoluene benzene. NBS (2.62 g , 14.72 mmol) was dissolved in 30 ml of H2O then the 
mixture was added dropwise to the reaction flask, Stirred and illuminated with a 60 W 
incandescent light bulb for 27 h, Reaction was monitored by TLC. Crude was collected from the 
reaction flask, extracted with 15 ml ethyl acetate and the organic phase washed with 15 ml 
brine, dried over Na2SO4, filtered, and concentrated on rotavap. Crude underwent purification 
by means of recrystallization in ethanol/water (5:1). Crystals was filtered, washed with water, 





(hexane/ethyl acetate, 9:1); 1H-NMR (CDCl3, 400 MHz) δ =7.93 (d, J= 8, 2H), 7.48 (d, J= 8, 2H), 
4.51 (s, 2H), 2.94 (t, J = 8 Hz,  2H), 1.73 (m, 2H), 1.38-1.31 (m, 6H), 0.89 (t, J = 4 Hz, 3H); 13C-
NMR (CDCl3, 100 MHz) δ = 195.8 ,167.1, 138.5, 132.9, 127.7, 125.2, 124.6, 122.8, 121.1, 56.4, 
34.7, 28.2, 27.6, 25.0, 20.3, 18.5, 17.0, 10.0. The data is consistent with literature [169]. Appenix 
6. 
5.2.2.1.3 Synthesis of the Wittig salt  
 
1-(4-(bromomethyl) phenyl) heptan-1-one 8 (1.73 g, 6.1 mmol) was dissolved in 50 ml of 
acetone followed by addition of triphenylphosphine (1.86 g, 6.58 mmol). The reaction mixture 
stirred under reflux for 3h at 65C, the reaction was monitored by TLC .Crude was cooled down 
forming crystals, filtrated under vacuum filtration, rinsed with diethyl ether, and dried in a 
desiccator. White clear crystals was obtained (1.58 g, 82 %) of the salt 9. m.p.: 237-236 C.  TLC; 
Rf = 0.7 (hexane/ethyl acetate, 9:1); IR (cm-1) 3044, 2925, 2852, 2771, 1679, 1436, 689; HRMS 
(ESI) m/z: [M+H]+ Calcd. For C32H34OP 453.23, found 453.2300 ; 1H-NMR (CDCl3, 400 MHz) δ 
=7.80-7.75 (m, 10H), 7.68 (d, J=8 Hz, 2H), 7.63 (dd, J= 4, 16 Hz, 5H), 7.60 (d, J=4 Hz,2H), 7.28 (d, 
J= 4 Hz, 1H) , 7.26 (d, J=4 Hz,1H), 5.64 (d, J= 16 Hz, 2H), 2.85 (t, J = 8 Hz, 2H), 1.66 -1.63 (m, 5H), 
1.36-1.30 (m, 7H), 0.88 (t, J=4 Hz, 3H); 13C-NMR (CDCl3, 100 MHz) δ = 199.8, 142.4, 136.8, 129.1, 









5.2.2.2 Wittig salt of the ether moiety containing compound 
 
 
5.2.2.2.1  Synthesis of O-alkylated p-cresol. 
 
Table 3. The trials towards the O-alkylated product. 
Trial Base Solvent Yield % 
A 13.6g  K2CO3 50 ml , CH3CN (3.837g, 72%) 
b 4.5g KOH 5:45 ml  (H2O , EtOH) (4.071g, 76%) 
                                                            
The commercially available p-cresol (3 g, 2.901 ml, and 27.77 mmol) was dissolved in a certain 
amount of the solvent with the base under stirring, followed by the addition of 1-bromohexane 
(4.94 g, 4.25 ml, and 30.547mmol). The reaction mixture refluxed with stirring at 85C under 
N2 gas for 24 h, Reaction was monitored by TLC. The reaction mixture removed from heat 
source and gravity filtered off from the access of the base, rinsed with with DCM and the crude 
was concentrated in a rotavap. Work up on the crude was done by washing with 100 ml NaOH 
(2x), H2O (2x), brine (1x), the organic phase was extracted with DCM and dried over Na2SO4, 
filtered and finally concentrated on rotavap. The crude was pure no further purification was 
done to the crude product. TLC; Rf =0.5 (hexane/ ethyl acetate, 9.5: 0.5); 1H-NMR (CDCl3, 400 
MHz) δ =7.11 (d, J= 8 Hz, 2H), 6.84 (d, J= 8 Hz, 2H), 3.95 (t, J= 8 Hz,  2H) , 2.32 (s, 3H), 1.82-1.77 





=157.0, 129.8, 129.6, 114.3, 68.0 , 31.6 , 29.3, 25.7, 22.6 , 20.4 , 14.0. The data is consistent 
with literature [170, 171]. Appenix 8. 
5.2.2.2.2  Synthesis of benzylic brominated p-cresol derivative. 
 
Table 1. Reaction optimization towards the bromination of the benzylic ether 
Trial Solvent Reaction 
time 
Equivalency 
( cpd 11: 
NBS) 
Yield% product 
1 CHCL3 9h (3*3) 1:3 19 % Dibromo 
2 CHCL3 9h (3*3) 3:1 83 % mix 
3 DCM 6h (2*3) 3:1 48% monobromo 
                                 
1-(hexyloxy)-4-methylbenzene 11 (3.5 g,18.21mmol,3eq) was dissolved in 121.4 ml chloroform 
,NBS (3*0.35, 5.95mmol,1eq) was added to the reaction flask in three equal portions in each 
addition few mg of benzoyl peroxide was also added , refluxed at 68C for. Upon completion of 
reaction, the mixture was cooled and filtered. Crude product washed with saturated NaHCO3 
solution (100ml), brine (100 ml), dried over Na2SO4, filtered and concentrated on rotavap. 
Purification by vacuum distillation ≈4 torr and remaining amount separated using short path 
distillation (kugler-distill) affording pure colorless liquid of 1-(bromomethyl)-4-(hexyloxy) 
benzene 12. 1H-NMR (CDCl3, 400 MHz,) δ =7.10 (d, J= 12 Hz, 2H), 6.83 (d, J= 8 Hz, 2H), 5.30 (s, 





0.94 (t, J= 8 Hz,  3H);13C-NMR (CDCl3, 100 MHz) δ =157.0, 129.8, 114.3, 76.6 ,68.0, 31.6, 29.3, 
25.7, 22.6, 20.4, 14.0. The data is consistent with literature [170]. Appenix 9. 
5.2.2.2.3  Synthesis of the Wittig salt  
 
The previously prepared compound 12 (0.565g, 2.07mmol) was dissolved in 20ml acetone , 
triphenylphosphine (0.58g, 2.25mmol) was added to the reaction mixture and stirred for 3h 
under reflux at 65C the reaction was monitored by TLC. After complete reaction, the crude 
concentrated in a rotavap. The crude washed with ethyl acetate and filtered affording white 
powder (0.676g, 72%) of(4-(hexyloxy) benzyl)triphenylphosphonium bromide 13. m.p.: 360-
361C .TLC : Rf = 0.2 (hexane/ethyl acetate, 5:1) ; IR (cm-1) 3053, 2926, 2856, 1606, 1508, 1436, 
843; HRMS (ESI) m/z: [M+H]+ Calcd. For C31H34OP 465.23, found 465.2300 ; 1H NMR (CDCl3, 400 
MHz) δ =7.72-7.63 (m, 8 H), 7.58 (d, J= 4 Hz,2H), 7.56 (d, J= 4, 2H), 7.54 (d, J=4,1H), 6.92 (dd, J= 
4, 16 Hz, 2H), 6.57 (d, J=8 Hz, 2H), 5.23 (d, J= 16 Hz, 2H), 3.78 (t, J= 8Hz,  2H), 1.69-1.62 (m, 2H), 
1.38-1.31 (m, 2H), 1.26-1.23 (m, 4H), 0.82 (t, J= 8 Hz, 3H);13C NMR (CDCl3, 100MHz) δ =159.2, 
134.9, 134.4, 130.0, 118.4, 117.5, 114.8, 68.0, 31.5, 29.1, 25.6, 22.5, 14.0. The data is consistent 
with literature [170, 171]. Appenix 10. 
5.2.3  Synthesis of the alkene via Wittig coupling of the ketone partner. 
 
The Wittig salt 9 (0.79g, 1.44 mmol) was dissolved in minimum amount of THF at 0C in a dry 
and clean round bottomed flask under N2 gas.  Meanwhile Potassium t-butoxide (0.3 g, 2.67 





added slowly during 15 min to the reaction flask while stirring at 0C. After complete addition, 
cooling source was removed and the reaction mixture was continued stirring for 20 min at room 
temperature. A solution of the aldehyde 5 (0. 27g, 1.105 mmol) in THF was added slowly to the 
reaction mixture at room temperature. After complete addition the reaction mixture continued 
stirring for 1-2 hr, reaction progress was monitored by TLC. After complete reaction the solvent 
was removed in a rotavap, the crude was washed with water and extracted with ethyl acetate, 
and organic phases was collected, dried over Na2SO4, and concentrated on rotavap. The crude 
was further purified by means of column chromatography (hexane, ethyl acetate, 10:1) 
affording yellow liquid (0.22 g, 47%). TLC; Rf =0.35 (hexane/ethyl acetate, 5:1); HRMS (ESI) m/z: 
[M+Na]+ Calcd. For C26H38O5Na 453.26, found 453.2610; IR (cm-1) 2955, 2865, 1732, 1682, 
1218, 1030, 856; 1H-NMR (CDCl3, 400 MHz) δ =7.94 (d , J= 8 Hz,  2H),7.43 (d, J= 8 Hz, 1H) 7.33 
(d , J= 8 Hz, 1H), 6.74 (d, J= 8 Hz, 1H), 5.83 (t, J= 12 Hz, 1H), 4.92-4.88 (m, 1H), 4.21-4.18 (m, 
1H), 4.14-4.11 (m, 3H), 2.95 (t, J= 8 Hz, 2H), 2.34 (t, J= 8 Hz, 2H), 2.04 (s, 2H),  1.72-1.66 (m, 
2H), 1.63-1.65 (m, 2H), 1.58-1.22 (m, 18H), 1.25-1.22 (m, 5H), 0.89 (t,  J= 8 Hz,  3H); 13C-NMR 
(CDCl3, 100MHz) δ=199.9, 173.2, 140.6, 135.9, 132.4, 129.5, 128.7, 128.1, 108.46, 78.1,74.0, 
60.2, 38.6, 34.0, 31.6, 29.8, 29.0, 28.3, 25.6, 24.3, 22.5, 21.8, 14.2. Appenix 11. 
5.2.4  Synthesis of the alkene via Wittig coupling of the ether partner 
 The Wittig salt 13 (0.2g, 0.44 mmol) was dissolved in minimum amount of THF at 0C in a dry 
and clean round bottomed flask under N2 gas.  Meanwhile, Potassium t-butoxide (0.11 g, 0.90 
mmol) was dissolved in minimum amount of THF at in another flask, the base solution was 
added slowly during 15 min to the reaction flask while stirring at 0C. After complete addition, 
cooling source was removed and the reaction mixture was continued stirring for 20 min at room 
temperature. A solution of the aldehyde 5 (0. 1g, 0.40 mmol) in THF was added slowly to the 
reaction mixture at room temperature. After complete addition the reaction mixture continued 





was removed in a rotavap, the crude was washed with water and extracted with ethyl acetate, 
and organic phases was collected, dried over Na2SO4, and concentrated on rotavap. The crude 
was further purified by means of column chromatography (pentane, ethyl acetate, 9:1) 
affording yellow liquid (0.055 g, 30%) of the alkene 14.  TLC; Rf =0.36 (hexane/ethyl acetate, 
5:1); IR (cm-1) 2933, 1733, 1510, 1174, 1025, 839; HRMS (ESI) m/z: [M+Na]+ Calcd. 
for C25H38O5Na 441.26 , found 441.2600; 1H-NMR (CDCl3,400 MHz) δ=7.08 (d, J= 8 Hz, 2H), 6.79 
(d, J= 8 Hz, 2H), 6.57 (d, J= 12 Hz,1H), 5.54 (t, J= 12 Hz, 1H), 4.89 (t, J= 4 Hz, 1H), 4.13-4.09 (m, 
2H), 4.06-4.03 (m, 5H), 3.87 (t, J= 8 Hz 2H), 2.26 (t, J= 12 Hz, 2H), 1.96 (s, 5H), 1.72-1.68 (m, 
3H), 1.62-1.52 (m, 2H), 1.42 (s, 5H), 1.38-1.35 (m, 2H), 1.26 (s, 6H), 1.19-1.16 (m, 8H), 0.88 (t, 
J= 8 Hz, 3H); 13C-NMR (CDCl3, 100 MHz) δ=173.3, 171.0, 158.5, 133.1, 129.8, 128.5, 125.7, 
114.2, 108.1, 78.2, 74.3, 67.9, 60.3, 34.1, 31.5, 30.0, 29.1, 28.3, 25.6, 22.5, 21.8, 20.9,14.1. 
Appenix 12. 
5.2.5 Hydrolysis of the acetonid in the ketone containing analogue 
 
The previously synthesized alkene 15 (0.022g, 0.05mmol) was dissolved in a mixture of 
acetonitrile and water (1:1) with stirring at 0C.  TFA (0.8 ml) was added dropwise to the stirring 
mixture at 0C after complete addition the ice bath was removed and the reaction kept stirring 
at room temperature for 1h. The reaction progress was monitored by TLC. After complete 
reaction it was slowly quenched with 2ml sodium bicarbonate and extracted several times with 
ethyl acetate the combined organic phase was washed with water and brine, dried over 
sod.sulfate and concentrated in a rotavap affording oily green oily liquid (0.012,70 %) of lactone 
16. TLC; Rf =0.45(CHCl3/MeOH, 9.8:0.2); IR (cm-1) 2928, 2857, 2248, 2159, 1729, 1679, 1603, 
1239, 1049; HRMS (ESI) m/z: [M+Na]+ Calcd. for C21H28O4Na 367.19, found 367.1883; 1H-NMR 
(400 MHz, CDCl3) δ=7.88-7.82 (m, 2H), 7.33 (dd, J=8, 32 Hz,2H), 6.68 (t, J=8 Hz,  1H), 5.83-5.73 
(m, 1H), 4.40-4.36 (m, 1H), 4.24-4.21 (m, 1H), 3.49 (bs, 1H), 2.87 ( t, J=8 Hz, 2H), 2.58-2.49 (m, 





3H); 13C-NMR (CDCl3, 100 MHz) δ=200.1, 171.4, 140.5, 136.1, 133.8, 129.7, 128.9, 128.3, 83.1, 
69.7, 68.9, 38.7, 31.6, 29.8, 29.0, 24.4, 22.5, 18.3, 14.0. Appenix 13. 
5.2.6  Hydrolysis of acetonid of the ether containing analogue 
 
The previously synthesized alkene 14 (0.022g, 0.05mmol) was dissolved in 2ml THF , 2ml of 1N 
HCl was added dropwise to the stirring mixture at 0C after complete addition the ice bath was 
removed and the reaction kept stirring at room temperature overnight. The reaction progress 
was monitored by TLC. After complete reaction it was slowly quenched with 2ml NaOH and 
extracted several times with ethyl acetate the combined organic phase was washed with water 
and brine, dried over sodium sulfate and concentrated in a rotavap affording colorless liquid. 
TLC; Rf =0.45(CHCl3/MeOH, 9.8:0.2); IR (cm-1) 2927, 2857, 1711, 1606, 1510, 1174, 1049, 839; 
HRMS (ESI) m/z: [M+Na]+ Calcd. for C21H28O4Na 355.19 found 355.1884 ; 1H-NMR (CDCl3, 400 
MHz) δ= 7.19 (s, 1H), 7.09 (d, J= 8 Hz, 1H), 6.79 (d, J= 12 Hz, 2H), 6.58 (d, J= 12 Hz, 1H), 5.55 (t, 
J= 8 Hz, 1H), 4.92-4.88 (m, 1H), 4.14-4.09 (m, 1H), 4.04 (q, J= 8 Hz, 2H), 3.89 (t, J= 8 Hz, 2H), 
2.27 (t, J= 4 Hz, 2H), 1.73-1.69 (m, 3H), 1.61-1.53 (m, 2H), 1.43 (s, 3H), 1.41-1.36 (m, 2H), 1.28-
1.27 (m, 6H), 1.19-1.15 (m, 3H), 0.84 ( t, J= 8 Hz, 3H) ; 13C-NMR (CDCl3, 100 MHz,) δ= 172.3, 
157.5, 132.1, 128.8, 127.4, 124.7, 113.2, 107.1, 77.2, 73.3, 67.0, 59.2, 33.1, 30.5, 29.0, 28.1, 
27.4, 24.7, 21.5, 20.8, 13.0. Appenix 14. 
5.2.7 Ullmann approach 






The commercialy available 4-bromophenol 19 (1g, 5.78 mmol) was dissolved in 20 ml 
acetonitrile. (1.59g, 11.56mmol) potassium carbonate was added to the reaction mixture under 
stirring for 5 min before (1.048 g, 6.35 mmol)1-bromohexane slowly added to the reaction flask 
and the mixture left refluxing with stirring under N2 gas for 24h.  
The reaction was monitored by TLC. After reaction completion the crude left to cool down and 
the excess of the base was filtered off and rinsed with acetonitrile. The crude concentrated in 
rotvap before washing with 1M NaOH to remove the unreacted phenol derivatives, H2O, and 
brine and the crude was extracted with ethyl acetate and dried over Na2SO4, filtered and 
concentrated in a vacuo affording colorless oil (1.27g, 85%). The product was quit pure after 
the workup, no further purification was done on it. TLC; Rf =0.36 (heptane/ethyl acetate, 
9.8:0.2); 1H-NMR (CDCl3, 400 MHz) δ=7.41 (d, J= 8 Hz  ,2H), 6.82 (d, J= 8, 2H), 3.96 (t, J= 4Hz, 
2H), 1.85-1.78 (m, 2H), 1.50-1.39 (m, 6H), 0.96 (t, J= 8Hz, 3H); 13C-NMR (CDCl3, 100 MHz) 
δ=158.2, 132.2, 116.3, 112.5, 68.2, 31.6, 29.1, 25.7, 22.6, 14.0. Appenix 15. 
5.2.7.2 Synthesis of Ullmann ether. 
 
(10%) CuI, (10%) 2,4,7,8 Me2Ph4, and Cs2CO3 were added in reaction tube with the (0.0898 g, 
0.349 mmol) of the previously synthesized 1-bromo-4-(hexyloxy) benzene 20. The reaction 
tube was evacuated from air and backfilled with argon. (0.129 g, 0.523 mmol) of the aldehyde 
was added with 5ml of toluene through a syringe to the reaction mixture. The reaction tube 
was submitted to the Microwave apparatus under 160C for 5h. The reaction was monitored 
every hour during the reaction time. After 5h the crude was filtered and washed with ethyl 
acetate. The product couldn’t be indicated, the TLC showed the presence of the two starting 
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JHAI-2-5_4 #1 RT: 0.02 AV: 1 NL: 1.65E7
T: FTMS + p ESI Full ms [100.00-300.00]





























C 8 H 14 O 4 Na 229.10
C 9 H 18 O 5 Na
243.12
C 10 H 20 O 5 Na142.16
157.09
C 8 H 13 O 3
199.08
295.12















































UNALK_151002103248 #1 RT: 0.01 AV: 1 NL: 6.36E7
T: FTMS + p ESI Full ms [200.00-500.00]

















































































red #1 RT: 0.01 AV: 1 NL: 8.14E7
T: FTMS + p ESI Full ms [150.00-500.00]





























C 12 H 22 O 5 Na
301.08
429.24
C 27 H 34 O 3 Na
317.05
337.10
C 18 H 18 O 5 Na
203.06181.08
247.15





























JHAI-2-10-2 #1 RT: 0.01 AV: 1 NL: 2.57E7
T: FTMS + p ESI Full ms [150.00-700.00]





























C 13 H 24 O 6 Na
267.12
C 12 H 20 O 5 Na 329.14
C 19 H 21 O 5
441.30
C 26 H 42 O 4 Na
689.42
635.11543.28
JHAI-2-7-2_pos #1 RT: 0.00 AV: 1 NL: 2.45E7
T: FTMS + p ESI Full ms [150.00-450.00]





























C 12 H 20 O 5 Na
371.20353.16
309.13
C 14 H 22 O 6 Na153.14 393.30
C 24 H 41 O 4 423.20
243.12










































































JHAI-1-20wit_MeOH #1 RT: 0.01 AV: 1 NL: 3.22E8
T: FTMS + p ESI Full ms [200.00-1000.00]





























C 32 H 34 O P
395.16
C 27 H 24 O P 545.14
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JHAI-1-30-2 #1 RT: 0.01 AV: 1 NL: 6.88E8
T: FTMS + p ESI Full ms [400.00-550.00]





























C 31 H 34 O P
455.24
531.15
C 31 H 33 O Br P
407.21
C 26 H 32 O 2 P
467.25
C 32 H 36 O P
439.22
C 30 H 32 O P
504.98
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bi_150930155903 #1 RT: 0.01 AV: 1 NL: 1.47E7
T: FTMS + p ESI Full ms [150.00-500.00]





























C 26 H 38 O 5 Na
373.24
C 23 H 33 O 4329.14
C 19 H 21 O 5
269.14
C 12 H 22 O 5 Na
169.11
C 8 H 19 Na P
408.25
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h_151007161342 #1 RT: 0.01 AV: 1 NL: 3.74E7
T: FTMS + p ESI Full ms [400.00-600.00]





























C 25 H 38 O 5 Na
501.26
C 32 H 37 O 5
577.24517.26436.31 469.33
457.23









h_a #1 RT: 0.02 AV: 1 NL: 4.55E6
T: FTMS + p ESI Full ms [400.00-600.00]





























C 25 H 38 O 5 Na
501.26
C 32 H 37 O 5
517.26
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AB-180_151009115758 #1-4 RT: 0.02-0.11 AV: 4 NL: 1.81E6
T: FTMS + p ESI Full ms [200.00-500.00]


































C 12 H 22 O 5 Na = 269.1359
0.9996 ppm
413.2301
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etherhydhcl_151029153725 #1-5 RT: 0.00-0.11 AV: 5 NL: 7.66E7
T: FTMS + p ESI Full ms [200.00-600.00]





























C 20 H 28 O 4 Na = 355.1885
-0.1038 mmu
401.2298
C 22 H 34 O 5 Na = 401.2304
-0.5499 mmu
441.2611
C 25 H 38 O 5 Na = 441.2617
-0.5882 mmu
315.1956













































































































































































 3000  2800  2600  2400  2200  2000  1800  1600  1400  1200  1000   800
   100
    95
    90
    85
    80
    75
    70
    65
    60
Wavenumber
%
T
ra
n
s
m
it
ta
n
c
e
 
 
134 
 
 
Appendix 15 
 
 
 
 
 
 
 
 
 
 
 
135 
 
 
 
 
 
 
136 
 
 
 
 
